

# Table of Contents

---

<b>About the Editors</b> .....	v
<b>About the Contributors</b> .....	ix
<b>Table of Chapters</b> .....	xxxvii
<b>Table of Contents</b> .....	xli
<b>About This Book</b> .....	cxv
<b>Acknowledgments</b> .....	cxvii
<b>Glossary and Abbreviations</b> .....	cxix
<b>Current Trends in Health Care M&amp;A</b> .....	cli
<b>Today's Health Care Legal and Regulatory Environment and Its Impact on the Health Care Marketplace</b> .....	clxxiii

## VOLUME 1

### PART I

#### STRUCTURING HEALTH CARE M&A TRANSACTIONS

##### Chapter 1 Basic Transaction Structures in Health Care M&A

*Andrew L. Bab & Dmitriy A. Tartakovskiy*

<b>Acquisition of the Whole Business</b> .....	1-3
Q 1.1 What is a whole business acquisition? .....	1-3
Q 1.1.1 What is a stock purchase? .....	1-3
Q 1.1.2 What is a merger? .....	1-4
Q 1.1.3 What is a tender offer? .....	1-5
Q 1.1.4 What is an asset purchase? .....	1-9
<b>Product and Portfolio Acquisitions</b> .....	1-10
Q 1.2 What is a product or portfolio acquisition? .....	1-10

<b>Option Transactions</b> .....	1-11
Q 1.3 What are typical M&A structures in the pharmaceutical and biotechnology industries? .....	1-11
Q 1.4 What are the key terms of an option transaction? .....	1-11
Q 1.4.1 What is the purpose of the up-front payment? .....	1-12
Q 1.4.2 What determines the duration of the option? .....	1-16
Q 1.4.3 How is the option transaction documented? .....	1-19
<b>Other Structuring Considerations</b> .....	1-19
Q 1.5 What other factors may affect the structuring decision in health care M&A transactions? .....	1-19
Q 1.6 When should the transaction be structured as a stock purchase as opposed to an asset purchase? .....	1-20
Q 1.6.1 What are assumed vs. excluded assets and liabilities? .....	1-21
Q 1.6.2 What are the tax implications of structuring the transaction as a stock or asset deal? .....	1-23
Q 1.6.3 How does the transaction structure affect the need to obtain regulatory approvals and third-party consents? .....	1-25
Q 1.6.4 What are relevant documentary considerations? .....	1-27

## **Chapter 2 Contingent Payments**

*Andrew L. Bab*

<b>Contingent Value Rights</b> .....	2-2
Q 2.1 What are contingent value rights? .....	2-2
Q 2.1.1 What are stock-based CVRs and when are they used? .....	2-2
Q 2.1.2 What are event-driven CVRs? .....	2-3
Q 2.2 What events can trigger payments under event-driven CVRs? .....	2-4
Q 2.3 Are event-driven CVRs equity, debt, or something else entirely? .....	2-5
Q 2.4 When is an event-driven CVR treated as a security and not a contract right? .....	2-5
Q 2.5 How are CVRs treated from an accounting perspective? .....	2-6
Q 2.6 Must issuers of CVRs exert a certain level of effort to bring about the agreed milestones? .....	2-8
Q 2.6.1 What efforts obligations may courts imply? .....	2-8
Q 2.6.2 What efforts obligations do health care issuers typically include in their CVR agreements? .....	2-9

## Table of Contents

---

Q 2.7	What special issues confront private equity sponsors who buy health care companies and who wish to use CVRs? .....	2-14
<b>Earnouts Compared to CVRs</b> .....		2-15
Q 2.8	What is an earnout? .....	2-15
Q 2.9	What triggers are used in earnouts? .....	2-15
Q 2.10	Can earnouts pay the buyer rather than the seller, if the target performs poorly?.....	2-16
Q 2.11	Do earnouts last as long as CVRs? .....	2-16
Q 2.12	Are earnouts more likely than CVRs to be enforced? .....	2-16
Q 2.13	What are the income tax consequences of earnouts? .....	2-17

### Chapter 3 Purchase Price Adjustments

*Andrew L. Bab, Dmitriy A. Tartakovskiy &  
Jonathan L. Lubin*

<b>Functions of Purchase Price Adjustments</b> .....		3-2
Q 3.1	What are the functions of a purchase price adjustment? .....	3-2
<b>Balance Sheet Adjustments</b> .....		3-4
Q 3.2	What is the most common type of purchase price adjustment used in health care M&A transactions? .....	3-4
Q 3.3	What is a working capital adjustment?.....	3-4
Q 3.3.1	How should working capital be defined in the agreement?.....	3-6
Q 3.3.2	What is the appropriate baseline for a working capital adjustment?.....	3-9
Q 3.3.3	What accounting principles should be used in calculating the working capital adjustment? .....	3-11
Q 3.3.4	What are the mechanics of a working capital adjustment?.....	3-12
Q 3.4	What other types of balance sheet adjustments are used in health care acquisitions? .....	3-14
<b>Other Types of Purchase Price Adjustments</b> .....		3-15
Q 3.5	What other types of purchase price adjustments are used in health care M&A transactions? .....	3-15
Q 3.5.1	What are event-driven purchase price adjustments?.....	3-15
Q 3.5.2	What are liability-driven purchase price adjustments?.....	3-17

<b>Purchase Price Adjustments Versus Indemnification</b> .....	3-18
Q 3.6 What is the difference between a purchase price adjustment and indemnification?.....	3-18
Q 3.7 What is the interaction between a working capital adjustment and indemnification provisions? .....	3-19
<b>Dispute Resolution</b> .....	3-20
Q 3.8 How are disputes about purchase price adjustments typically resolved? .....	3-20

## **Chapter 4 License-and-Collaboration Agreements**

*Kevin A. Rinker & Henry Lebowitz*

<b>Scope of the License</b> .....	4-2
Q 4.1 What are the principal terms of a license grant for a pharmaceutical product? .....	4-2
Q 4.1.1 Should a license be exclusive or nonexclusive?.....	4-3
Q 4.1.2 Should the license cover one or more fields of use or should the field of use be unlimited?.....	4-3
Q 4.1.3 Should the license cover one or more jurisdictions or be worldwide?.....	4-4
<b>Payments</b> .....	4-5
Q 4.2 What are the typical economic arrangements in a license? .....	4-5
Q 4.2.1 What are up-front payments? .....	4-5
Q 4.2.2 What are milestone payments? .....	4-5
Q 4.2.3 What are royalties? .....	4-6
Q 4.3 Are there other types of payments?.....	4-7
<b>Assigning the Responsibilities of the Parties</b> .....	4-8
Q 4.4 Which party is typically responsible for development of the product?.....	4-8
Q 4.5 Which party is typically responsible for filing and maintaining New Drug Applications and conducting related studies? .....	4-8
Q 4.6 Which party is responsible for prosecution of trademarks and patents?.....	4-9
Q 4.7 When should the parties consider a co-promotion arrangement? .....	4-9

*Table of Contents*

---

Q 4.8	Should the licensee seek a right of first negotiation, first offer, or first refusal? .....	4-10
Q 4.9	Should the license-and-collaboration agreement include a noncompetition covenant? .....	4-10
Q 4.10	Which party is typically responsible for manufacturing? .....	4-11
Q 4.10.1	Should the licensee have manufacturing transfer assistance from the licensor? .....	4-11
Q 4.11	Under what circumstances may each party terminate the agreement? .....	4-12

## **Chapter 5    Joint Ventures and Strategic Alliances**

*Sarah A.W. Fitts*

<b>Objectives</b> .....	5-2	
Q 5.1	Why create a joint venture or strategic alliance in the health care industry? .....	5-2
Q 5.1.1	Is capital the only reason to consider a joint venture or strategic alliance? .....	5-3
Q 5.2	What additional motivations might health care service providers have for creating joint ventures and strategic alliances? .....	5-5
Q 5.3	What additional motivations might pharmaceutical and biotechnology companies have for creating joint ventures and strategic alliances? .....	5-6
Q 5.4	What factors contributed to the recent rise in joint ventures and strategic alliances in the health care industry? .....	5-7
Q 5.5	How has COVID-19 impacted joint ventures and strategic alliances in the health care industry? .....	5-9
<b>Health Care Providers</b> .....	5-10	
Q 5.6	What are common strategic alliances involving health care service providers? .....	5-10
Q 5.7	When might a joint venture be appropriate for a hospital or other health care service provider? .....	5-11
Q 5.8	What other factors should health care providers keep in mind when determining whether to form a joint venture? .....	5-17
<b>Pharmaceutical and Biotech Companies</b> .....	5-18	
Q 5.9	What are common joint ventures and strategic alliances involving pharmaceutical and biotechnology companies? .....	5-18

## HEALTH CARE MERGERS & ACQUISITIONS AB

---

Q 5.10	What factors influence the structure of the pharmaceutical or biotechnology joint venture or strategic alliance? .....	5-23
Q 5.10.1	What concerns may influence the allocation of control in pharmaceutical and biotechnology joint ventures and strategic alliances? .....	5-24
Q 5.11	How should the parties deal with the possibility of termination of the joint venture? .....	5-26
<b>Examples</b>	.....	5-27
Q 5.12	What are some recent examples of joint ventures in health care services? .....	5-27
Q 5.13	What are some recent examples of strategic alliances in health care services? .....	5-34
Q 5.14	What are some recent examples of joint ventures in pharmaceuticals and biotechnology?.....	5-37
Q 5.15	What are some recent examples of strategic alliances in pharmaceuticals and biotechnology?.....	5-38

## Chapter 6 Transfer of Regulatory Approvals, Licenses, and Clearances

*Paul D. Rubin, Melissa B. Runsten & Carey B. Nuttall*

<b>Drugs and Biologics</b>	.....	6-2
Q 6.1	Is it possible to transfer ownership of a New Drug Application or Abbreviated New Drug Application?.....	6-2
Q 6.2	Is it possible to transfer ownership of a Biologics License Application?.....	6-3
<b>Devices</b>	.....	6-4
Q 6.3	Is it possible to transfer ownership of a Premarket Approval? .....	6-4
Q 6.4	Is it possible to transfer ownership of a 510(k)?.....	6-5
<b>Investigational Products</b>	.....	6-7
Q 6.5	Is it possible to transfer ownership of an IND or IDE?.....	6-7

**Chapter 7 Regulatory Issues in Acquisitions of Health Insurers**

*Nicholas F. Potter, Robert M. Fettman &  
Matthew B. Parelman*

<b>General Considerations</b> .....	7-2
Q 7.1 When does a change of control occur? .....	7-2
Q 7.2 What are the basic regulatory approvals required in order to effect the acquisition of control of a health insurer?.....	7-2
Q 7.3 If the health insurer is a health maintenance organization, are any additional regulatory approvals required? .....	7-4
Q 7.4 As a practical matter, what is the best way to manage and coordinate all the jurisdictions where filings are required? .....	7-5
<b>Form A</b> .....	7-6
Q 7.5 What information is required to complete the Form A change-of-control filing? .....	7-6
Q 7.6 Is information submitted with a Form A confidential? .....	7-7
Q 7.7 In addition to the insurer's domiciliary regulator, do any other states' insurance regulators have to approve a change of control? .....	7-8
<b>Form E</b> .....	7-9
Q 7.8 When is a Form E required? .....	7-9
<b>Approval Process</b> .....	7-10
Q 7.9 Once the filings are made, how long will it take to receive an approval?.....	7-10
<b>Additional Approvals and Filings</b> .....	7-10
Q 7.10 What if the insurer being acquired is a third-party administrator or utilization review agency? .....	7-10
Q 7.11 If the health insurer being acquired has entered into Medicare or Medicaid contracts, will additional approvals be required? .....	7-11
Q 7.12 Do federal premerger notification rules apply?.....	7-11
Q 7.13 Are there additional filings that may be required? .....	7-11

**Chapter 8 Not-for-Profit Issues**

*Michael Bolotin & Lena E. Smith*

**Public Interest** .....8-2

Q 8.1 What are the key differences between not-for-profit and for-profit organizations that can affect acquisitions and joint ventures? .....8-2

**Federal Tax-Exempt Status**.....8-3

Q 8.2 What are the benefits of tax-exempt status?.....8-3

    Q 8.2.1 If an organization has tax-exempt status, is all of its income exempt from federal tax?.....8-4

Q 8.3 What are the requirements for tax-exempt status?.....8-4

Q 8.4 What makes a health care provider’s activities “charitable” within the meaning of section 501(c)(3)?.....8-5

    Q 8.4.1 Are additional requirements imposed by the health care reform law? .....8-7

Q 8.5 Can a health insurance provider be tax-exempt?.....8-9

Q 8.6 Can an HMO be tax-exempt? .....8-11

Q 8.7 Can a tax-exempt, not-for-profit health care provider engage in transactions involving for-profit investors without jeopardizing its exempt status or incurring federal or state sanctions? .....8-11

**Joint Ventures** .....8-12

Q 8.8 Why are joint ventures between nonprofit and for-profit entities useful in the health care industry? .....8-12

Q 8.9 For the nonprofit to maintain its tax-exempt status, how must the joint venture be structured?.....8-13

    Q 8.9.1 What sort of control of the joint venture must the nonprofit maintain?.....8-13

    Q 8.9.2 What other factors are relevant?.....8-14

**State Law Requirements for Asset Sales** .....8-15

Q 8.10 What are typical state law requirements for approving a sale of assets by a nonprofit health care organization? .....8-15

    Q 8.10.1 What are the California requirements?.....8-15

    Q 8.10.2 What are the Massachusetts requirements? .....8-17

    Q 8.10.3 What are the New York requirements?.....8-18

## Table of Contents

---

<b>State Approval of For-Profit's Acquisition of Not-for-Profit Facilities</b> .....	8-21
Q 8.11 What special conditions can a state impose before granting approval of the acquisition of a nonprofit health care provider's facilities? .....	8-21
<b>Excess-Benefits Transactions</b> .....	8-24
Q 8.12 What sanctions can the Internal Revenue Service impose on individuals who receive "excess" benefits in a deal between a nonprofit and a for-profit entity?.....	8-24
Q 8.13 How does a charitable organization establish the rebuttable presumption that a transaction is not an excess-benefit transaction? .....	8-25
Q 8.13.1 What is approval by an authorized body? .....	8-27
Q 8.13.2 What is reliance on comparable data? .....	8-27
Q 8.13.3 What is the proper-documentation requirement? .....	8-28
<b>Chapter 9 Antitrust Considerations</b>	
<i>Michael Schaper &amp; Matthew J. Petrozziello</i>	
<b>Premerger Notification</b> .....	9-2
Q 9.1 What is the Hart-Scott-Rodino Act? .....	9-2
Q 9.2 What types of transactions are covered by the HSR Act?.....	9-2
Q 9.2.1 Are licensing transactions covered by the HSR Act?.....	9-3
Q 9.3 What information is required in the HSR filing? .....	9-4
Q 9.4 What happens after the HSR filing?.....	9-5
Q 9.5 What additional information is typically sought by the Assigned Agency during the initial waiting period? .....	9-5
Q 9.6 What happens after the initial waiting period? .....	9-6
Q 9.6.1 What information is sought by the formal request for additional information (or second request)? .....	9-7
Q 9.6.2 Once a second request has been issued, is there any possibility of the Agencies granting clearance without substantial compliance?.....	9-7
Q 9.6.3 How burdensome is compliance with a second request?.....	9-8
Q 9.7 Once the parties submit the information called for by the second request, how does the Assigned Agency proceed?.....	9-8
<b>Merger Analysis</b> .....	9-9
Q 9.8 What is merger analysis?.....	9-9
Q 9.9 What types of transactions are subject to merger analysis?.....	9-9

## HEALTH CARE MERGERS & ACQUISITIONS AB

---

Q 9.10	How is the relevant product market defined? .....	9-9
Q 9.10.1	How is the relevant product market defined for hospital mergers? .....	9-10
Q 9.10.2	How is the relevant product market defined for pharmaceutical mergers? .....	9-12
Q 9.10.3	How is the relevant product market defined for licensing arrangements? .....	9-14
Q 9.11	How is the relevant geographic market determined? .....	9-17
Q 9.11.1	How is the relevant geographic market determined for hospital mergers? .....	9-17
Q 9.11.2	How is the relevant geographic market determined for pharmaceutical mergers? .....	9-21
Q 9.12	What market conditions are considered in assessing market power? .....	9-22
Q 9.12.1	How might a merger impair competition in the relevant market? .....	9-23
Q 9.12.2	What types of procompetitive effects might outweigh any potential impairment of competition? .....	9-24
Q 9.13	What other “defenses” might be argued in the face of a post-merger market with competitive impairment? .....	9-28
Q 9.13.1	What is the “failing firm” defense? .....	9-28
Q 9.13.2	What is the “ease of entry” defense? .....	9-30
<b>Protections for Certain Health Care Mergers</b> .....		9-31
Q 9.14	Does the nonprofit status of a hospital affect the analysis of a merger involving the hospital? .....	9-31
Q 9.15	What transactions are protected under the state action immunity doctrine? .....	9-34
Q 9.16	What guidance is available from the antitrust authorities on health care merger analysis? .....	9-35
<b>Antitrust Considerations Applicable to Patent Pools</b> .....		9-36
Q 9.17	What are patent pools? .....	9-36
Q 9.18	What is the Agencies’ approach to reviewing patent pools? .....	9-37
Q 9.19	What guidance is available from the Agencies on the treatment of patent pools? .....	9-38

**Chapter 10 Valuation Issues**

*Dimitri Drone, Michael DeLuke & Neil Wadhvani*

**The Appraisal Process** .....10-3

Q 10.1 What is an appraisal? .....10-3

Q 10.2 Are appraisers and the appraisal process subject to professional standards?.....10-3

    Q 10.2.1 How do regulatory requirements in the health care industry relate to appraisal standards? .....10-4

    Q 10.2.2 What is the scope-of-work rule? .....10-4

    Q 10.2.3 What are the different types of valuation reports?.....10-5

Q 10.3 When is a valuation necessary? .....10-5

Q 10.4 What is the appropriate standard of value in a given case? .....10-6

    Q 10.4.1 What is the typical standard of value used in health care transactions? .....10-7

    Q 10.4.2 What is the typical standard of value used in the pharmaceutical and biotech industry? .....10-8

Q 10.5 What are the primary approaches to value? .....10-8

**Cost Approach**.....10-9

Q 10.6 What is the cost approach? .....10-9

Q 10.7 When is the cost approach most appropriate?.....10-9

Q 10.8 What are the strengths and weaknesses of the cost approach/asset-based approach? .....10-10

Q 10.9 How are intangible assets identified and categorized? .....10-11

    Q 10.9.1 What are market-related intangible assets?.....10-11

    Q 10.9.2 What are consumer-related intangible assets?.....10-12

    Q 10.9.3 What are contract-based intangible assets? .....10-12

    Q 10.9.4 What are technology-based intangible assets? .....10-12

**Market Approach**.....10-13

Q 10.10 What is the market approach?.....10-13

    Q 10.10.1 What is the guideline publicly traded company method? .....10-13

    Q 10.10.2 What is the guideline transactions method? .....10-14

    Q 10.10.3 What is the direct sales comparison method? .....10-15

Q 10.11 When is the market approach most appropriate? .....10-16

**Income Approach**.....10-17

Q 10.12 What is the income approach? .....10-17

Q 10.13 What is the discounted cash flow analysis? .....10-18

# Table of Contents

---

<b>About the Editors</b> .....	v
<b>About the Contributors</b> .....	ix
<b>Table of Chapters</b> .....	xxxvii
<b>Table of Contents</b> .....	xli
<b>About This Book</b> .....	cxv
<b>Acknowledgments</b> .....	cxvii
<b>Glossary and Abbreviations</b> .....	cxix
<b>Current Trends in Health Care M&amp;A</b> .....	cli
<b>Today's Health Care Legal and Regulatory Environment and Its Impact on the Health Care Marketplace</b> .....	clxxiii

## VOLUME 1

### PART I

#### STRUCTURING HEALTH CARE M&A TRANSACTIONS

##### Chapter 1 Basic Transaction Structures in Health Care M&A

*Andrew L. Bab & Dmitriy A. Tartakovskiy*

<b>Acquisition of the Whole Business</b> .....	1-3
Q 1.1 What is a whole business acquisition? .....	1-3
Q 1.1.1 What is a stock purchase? .....	1-3
Q 1.1.2 What is a merger? .....	1-4
Q 1.1.3 What is a tender offer? .....	1-5
Q 1.1.4 What is an asset purchase? .....	1-9
<b>Product and Portfolio Acquisitions</b> .....	1-10
Q 1.2 What is a product or portfolio acquisition? .....	1-10

<b>Option Transactions</b> .....	1-11
Q 1.3 What are typical M&A structures in the pharmaceutical and biotechnology industries? .....	1-11
Q 1.4 What are the key terms of an option transaction? .....	1-11
Q 1.4.1 What is the purpose of the up-front payment? .....	1-12
Q 1.4.2 What determines the duration of the option? .....	1-16
Q 1.4.3 How is the option transaction documented? .....	1-19
<b>Other Structuring Considerations</b> .....	1-19
Q 1.5 What other factors may affect the structuring decision in health care M&A transactions? .....	1-19
Q 1.6 When should the transaction be structured as a stock purchase as opposed to an asset purchase? .....	1-20
Q 1.6.1 What are assumed vs. excluded assets and liabilities? .....	1-21
Q 1.6.2 What are the tax implications of structuring the transaction as a stock or asset deal? .....	1-23
Q 1.6.3 How does the transaction structure affect the need to obtain regulatory approvals and third-party consents? .....	1-25
Q 1.6.4 What are relevant documentary considerations? .....	1-27

## **Chapter 2 Contingent Payments**

*Andrew L. Bab*

<b>Contingent Value Rights</b> .....	2-2
Q 2.1 What are contingent value rights? .....	2-2
Q 2.1.1 What are stock-based CVRs and when are they used? .....	2-2
Q 2.1.2 What are event-driven CVRs? .....	2-3
Q 2.2 What events can trigger payments under event-driven CVRs? .....	2-4
Q 2.3 Are event-driven CVRs equity, debt, or something else entirely? .....	2-5
Q 2.4 When is an event-driven CVR treated as a security and not a contract right? .....	2-5
Q 2.5 How are CVRs treated from an accounting perspective? .....	2-6
Q 2.6 Must issuers of CVRs exert a certain level of effort to bring about the agreed milestones? .....	2-8
Q 2.6.1 What efforts obligations may courts imply? .....	2-8
Q 2.6.2 What efforts obligations do health care issuers typically include in their CVR agreements? .....	2-9

## Table of Contents

---

Q 2.7	What special issues confront private equity sponsors who buy health care companies and who wish to use CVRs? .....	2-14
<b>Earnouts Compared to CVRs</b> .....		2-15
Q 2.8	What is an earnout? .....	2-15
Q 2.9	What triggers are used in earnouts? .....	2-15
Q 2.10	Can earnouts pay the buyer rather than the seller, if the target performs poorly?.....	2-16
Q 2.11	Do earnouts last as long as CVRs? .....	2-16
Q 2.12	Are earnouts more likely than CVRs to be enforced? .....	2-16
Q 2.13	What are the income tax consequences of earnouts? .....	2-17

### Chapter 3 Purchase Price Adjustments

*Andrew L. Bab, Dmitriy A. Tartakovskiy &  
Jonathan L. Lubin*

<b>Functions of Purchase Price Adjustments</b> .....		3-2
Q 3.1	What are the functions of a purchase price adjustment? .....	3-2
<b>Balance Sheet Adjustments</b> .....		3-4
Q 3.2	What is the most common type of purchase price adjustment used in health care M&A transactions? .....	3-4
Q 3.3	What is a working capital adjustment?.....	3-4
Q 3.3.1	How should working capital be defined in the agreement?.....	3-6
Q 3.3.2	What is the appropriate baseline for a working capital adjustment?.....	3-9
Q 3.3.3	What accounting principles should be used in calculating the working capital adjustment? .....	3-11
Q 3.3.4	What are the mechanics of a working capital adjustment?.....	3-12
Q 3.4	What other types of balance sheet adjustments are used in health care acquisitions? .....	3-14
<b>Other Types of Purchase Price Adjustments</b> .....		3-15
Q 3.5	What other types of purchase price adjustments are used in health care M&A transactions? .....	3-15
Q 3.5.1	What are event-driven purchase price adjustments?.....	3-15
Q 3.5.2	What are liability-driven purchase price adjustments?.....	3-17

<b>Purchase Price Adjustments Versus Indemnification</b> .....	3-18
Q 3.6 What is the difference between a purchase price adjustment and indemnification?.....	3-18
Q 3.7 What is the interaction between a working capital adjustment and indemnification provisions? .....	3-19
<b>Dispute Resolution</b> .....	3-20
Q 3.8 How are disputes about purchase price adjustments typically resolved? .....	3-20

## **Chapter 4 License-and-Collaboration Agreements**

*Kevin A. Rinker & Henry Lebowitz*

<b>Scope of the License</b> .....	4-2
Q 4.1 What are the principal terms of a license grant for a pharmaceutical product? .....	4-2
Q 4.1.1 Should a license be exclusive or nonexclusive?.....	4-3
Q 4.1.2 Should the license cover one or more fields of use or should the field of use be unlimited?.....	4-3
Q 4.1.3 Should the license cover one or more jurisdictions or be worldwide?.....	4-4
<b>Payments</b> .....	4-5
Q 4.2 What are the typical economic arrangements in a license? .....	4-5
Q 4.2.1 What are up-front payments? .....	4-5
Q 4.2.2 What are milestone payments? .....	4-5
Q 4.2.3 What are royalties? .....	4-6
Q 4.3 Are there other types of payments?.....	4-7
<b>Assigning the Responsibilities of the Parties</b> .....	4-8
Q 4.4 Which party is typically responsible for development of the product?.....	4-8
Q 4.5 Which party is typically responsible for filing and maintaining New Drug Applications and conducting related studies? .....	4-8
Q 4.6 Which party is responsible for prosecution of trademarks and patents?.....	4-9
Q 4.7 When should the parties consider a co-promotion arrangement? .....	4-9

*Table of Contents*

---

Q 4.8     Should the licensee seek a right of first negotiation, first offer, or first refusal? .....4-10

Q 4.9     Should the license-and-collaboration agreement include a noncompetition covenant? .....4-10

Q 4.10    Which party is typically responsible for manufacturing? .....4-11

    Q 4.10.1   Should the licensee have manufacturing transfer assistance from the licensor? .....4-11

Q 4.11    Under what circumstances may each party terminate the agreement? .....4-12

**Chapter 5    Joint Ventures and Strategic Alliances**

*Sarah A.W. Fitts*

**Objectives** .....5-2

Q 5.1     Why create a joint venture or strategic alliance in the health care industry? .....5-2

    Q 5.1.1   Is capital the only reason to consider a joint venture or strategic alliance? .....5-3

Q 5.2     What additional motivations might health care service providers have for creating joint ventures and strategic alliances? .....5-5

Q 5.3     What additional motivations might pharmaceutical and biotechnology companies have for creating joint ventures and strategic alliances? .....5-6

Q 5.4     What factors contributed to the recent rise in joint ventures and strategic alliances in the health care industry? .....5-7

Q 5.5     How has COVID-19 impacted joint ventures and strategic alliances in the health care industry? .....5-9

**Health Care Providers** .....5-10

Q 5.6     What are common strategic alliances involving health care service providers? .....5-10

Q 5.7     When might a joint venture be appropriate for a hospital or other health care service provider? .....5-11

Q 5.8     What other factors should health care providers keep in mind when determining whether to form a joint venture? .....5-17

**Pharmaceutical and Biotech Companies** .....5-18

Q 5.9     What are common joint ventures and strategic alliances involving pharmaceutical and biotechnology companies? .....5-18

## HEALTH CARE MERGERS & ACQUISITIONS AB

---

Q 5.10	What factors influence the structure of the pharmaceutical or biotechnology joint venture or strategic alliance? .....	5-23
Q 5.10.1	What concerns may influence the allocation of control in pharmaceutical and biotechnology joint ventures and strategic alliances? .....	5-24
Q 5.11	How should the parties deal with the possibility of termination of the joint venture? .....	5-26
<b>Examples</b>	.....	5-27
Q 5.12	What are some recent examples of joint ventures in health care services? .....	5-27
Q 5.13	What are some recent examples of strategic alliances in health care services? .....	5-34
Q 5.14	What are some recent examples of joint ventures in pharmaceuticals and biotechnology?.....	5-37
Q 5.15	What are some recent examples of strategic alliances in pharmaceuticals and biotechnology?.....	5-38

## Chapter 6 Transfer of Regulatory Approvals, Licenses, and Clearances

*Paul D. Rubin, Melissa B. Runsten & Carey B. Nuttall*

<b>Drugs and Biologics</b>	.....	6-2
Q 6.1	Is it possible to transfer ownership of a New Drug Application or Abbreviated New Drug Application?.....	6-2
Q 6.2	Is it possible to transfer ownership of a Biologics License Application?.....	6-3
<b>Devices</b>	.....	6-4
Q 6.3	Is it possible to transfer ownership of a Premarket Approval? .....	6-4
Q 6.4	Is it possible to transfer ownership of a 510(k)?.....	6-5
<b>Investigational Products</b>	.....	6-7
Q 6.5	Is it possible to transfer ownership of an IND or IDE?.....	6-7

**Chapter 7 Regulatory Issues in Acquisitions of Health Insurers**

*Nicholas F. Potter, Robert M. Fettman &  
Matthew B. Parelman*

<b>General Considerations</b> .....	7-2
Q 7.1 When does a change of control occur? .....	7-2
Q 7.2 What are the basic regulatory approvals required in order to effect the acquisition of control of a health insurer?.....	7-2
Q 7.3 If the health insurer is a health maintenance organization, are any additional regulatory approvals required? .....	7-4
Q 7.4 As a practical matter, what is the best way to manage and coordinate all the jurisdictions where filings are required? .....	7-5
<b>Form A</b> .....	7-6
Q 7.5 What information is required to complete the Form A change-of-control filing? .....	7-6
Q 7.6 Is information submitted with a Form A confidential? .....	7-7
Q 7.7 In addition to the insurer's domiciliary regulator, do any other states' insurance regulators have to approve a change of control? .....	7-8
<b>Form E</b> .....	7-9
Q 7.8 When is a Form E required? .....	7-9
<b>Approval Process</b> .....	7-10
Q 7.9 Once the filings are made, how long will it take to receive an approval?.....	7-10
<b>Additional Approvals and Filings</b> .....	7-10
Q 7.10 What if the insurer being acquired is a third-party administrator or utilization review agency? .....	7-10
Q 7.11 If the health insurer being acquired has entered into Medicare or Medicaid contracts, will additional approvals be required? .....	7-11
Q 7.12 Do federal premerger notification rules apply?.....	7-11
Q 7.13 Are there additional filings that may be required? .....	7-11

**Chapter 8 Not-for-Profit Issues**

*Michael Bolotin & Lena E. Smith*

**Public Interest** .....8-2

Q 8.1 What are the key differences between not-for-profit and for-profit organizations that can affect acquisitions and joint ventures? .....8-2

**Federal Tax-Exempt Status**.....8-3

Q 8.2 What are the benefits of tax-exempt status?.....8-3

    Q 8.2.1 If an organization has tax-exempt status, is all of its income exempt from federal tax?.....8-4

Q 8.3 What are the requirements for tax-exempt status?.....8-4

Q 8.4 What makes a health care provider’s activities “charitable” within the meaning of section 501(c)(3)?.....8-5

    Q 8.4.1 Are additional requirements imposed by the health care reform law? .....8-7

Q 8.5 Can a health insurance provider be tax-exempt?.....8-9

Q 8.6 Can an HMO be tax-exempt? .....8-11

Q 8.7 Can a tax-exempt, not-for-profit health care provider engage in transactions involving for-profit investors without jeopardizing its exempt status or incurring federal or state sanctions? .....8-11

**Joint Ventures** .....8-12

Q 8.8 Why are joint ventures between nonprofit and for-profit entities useful in the health care industry? .....8-12

Q 8.9 For the nonprofit to maintain its tax-exempt status, how must the joint venture be structured?.....8-13

    Q 8.9.1 What sort of control of the joint venture must the nonprofit maintain?.....8-13

    Q 8.9.2 What other factors are relevant?.....8-14

**State Law Requirements for Asset Sales** .....8-15

Q 8.10 What are typical state law requirements for approving a sale of assets by a nonprofit health care organization? .....8-15

    Q 8.10.1 What are the California requirements?.....8-15

    Q 8.10.2 What are the Massachusetts requirements? .....8-17

    Q 8.10.3 What are the New York requirements?.....8-18

## Table of Contents

---

<b>State Approval of For-Profit's Acquisition of Not-for-Profit Facilities</b> .....	8-21
Q 8.11 What special conditions can a state impose before granting approval of the acquisition of a nonprofit health care provider's facilities? .....	8-21
<b>Excess-Benefits Transactions</b> .....	8-24
Q 8.12 What sanctions can the Internal Revenue Service impose on individuals who receive "excess" benefits in a deal between a nonprofit and a for-profit entity?.....	8-24
Q 8.13 How does a charitable organization establish the rebuttable presumption that a transaction is not an excess-benefit transaction? .....	8-25
Q 8.13.1 What is approval by an authorized body? .....	8-27
Q 8.13.2 What is reliance on comparable data? .....	8-27
Q 8.13.3 What is the proper-documentation requirement? .....	8-28
<b>Chapter 9 Antitrust Considerations</b>	
<i>Michael Schaper &amp; Matthew J. Petrozziello</i>	
<b>Premerger Notification</b> .....	9-2
Q 9.1 What is the Hart-Scott-Rodino Act? .....	9-2
Q 9.2 What types of transactions are covered by the HSR Act?.....	9-2
Q 9.2.1 Are licensing transactions covered by the HSR Act?.....	9-3
Q 9.3 What information is required in the HSR filing? .....	9-4
Q 9.4 What happens after the HSR filing?.....	9-5
Q 9.5 What additional information is typically sought by the Assigned Agency during the initial waiting period? .....	9-5
Q 9.6 What happens after the initial waiting period? .....	9-6
Q 9.6.1 What information is sought by the formal request for additional information (or second request)? .....	9-7
Q 9.6.2 Once a second request has been issued, is there any possibility of the Agencies granting clearance without substantial compliance?.....	9-7
Q 9.6.3 How burdensome is compliance with a second request?.....	9-8
Q 9.7 Once the parties submit the information called for by the second request, how does the Assigned Agency proceed?.....	9-8
<b>Merger Analysis</b> .....	9-9
Q 9.8 What is merger analysis?.....	9-9
Q 9.9 What types of transactions are subject to merger analysis?.....	9-9

## HEALTH CARE MERGERS & ACQUISITIONS AB

---

Q 9.10	How is the relevant product market defined? .....	9-9
Q 9.10.1	How is the relevant product market defined for hospital mergers? .....	9-10
Q 9.10.2	How is the relevant product market defined for pharmaceutical mergers? .....	9-12
Q 9.10.3	How is the relevant product market defined for licensing arrangements? .....	9-14
Q 9.11	How is the relevant geographic market determined? .....	9-17
Q 9.11.1	How is the relevant geographic market determined for hospital mergers? .....	9-17
Q 9.11.2	How is the relevant geographic market determined for pharmaceutical mergers? .....	9-21
Q 9.12	What market conditions are considered in assessing market power? .....	9-22
Q 9.12.1	How might a merger impair competition in the relevant market? .....	9-23
Q 9.12.2	What types of procompetitive effects might outweigh any potential impairment of competition? .....	9-24
Q 9.13	What other “defenses” might be argued in the face of a post-merger market with competitive impairment? .....	9-28
Q 9.13.1	What is the “failing firm” defense? .....	9-28
Q 9.13.2	What is the “ease of entry” defense? .....	9-30
<b>Protections for Certain Health Care Mergers</b> .....		9-31
Q 9.14	Does the nonprofit status of a hospital affect the analysis of a merger involving the hospital? .....	9-31
Q 9.15	What transactions are protected under the state action immunity doctrine? .....	9-34
Q 9.16	What guidance is available from the antitrust authorities on health care merger analysis? .....	9-35
<b>Antitrust Considerations Applicable to Patent Pools</b> .....		9-36
Q 9.17	What are patent pools? .....	9-36
Q 9.18	What is the Agencies’ approach to reviewing patent pools? .....	9-37
Q 9.19	What guidance is available from the Agencies on the treatment of patent pools? .....	9-38

## HEALTH CARE MERGERS & ACQUISITIONS AB

---

Q 10.13.1	What are the main components of a DCF analysis? .....	10-18
Q 10.13.2	How are revenues estimated? .....	10-19
Q 10.13.3	How are expenses determined? .....	10-19
Q 10.13.4	What is the economic measure generated from the DCF? .....	10-19
Q 10.13.5	What is the reversion? .....	10-20
Q 10.13.6	What are the special considerations in applying the DCF analysis in health care transactions? .....	10-21
Q 10.14	What are the decision tree method and real options analysis? .....	10-22
<b>Reconciliation</b> .....		10-23
Q 10.15	What is the reconciliation? .....	10-23
<b>Other Functions for Valuation Opinions</b> .....		10-23
Q 10.16	What is the role of valuation in complying with acquisition accounting rules? .....	10-23
Q 10.17	How can a valuation be used to facilitate compliance with fraud and abuse laws? .....	10-24
Q 10.18	How can a valuation opinion be used to ensure compliance with the IRS regulations relating to “excess-benefit transactions”? .....	10-25
Q 10.19	What is the general process to conduct a fair market value analysis of services provided under a professional services arrangement using third-party benchmarking data? .....	10-26

## Chapter 11 Financing Drug Development

*Ilir Mujalovic & Derrick Lott*

<b>Background</b> .....		11-3
Q 11.1	How have companies addressed recent developments in the biopharmaceutical industry? .....	11-3
<b>Financing from Seed Capital to Initial Public Offering</b> .....		11-5
Q 11.2	How has the industry financed drug development historically? .....	11-5
Q 11.3	What is the current role of angel investors? .....	11-6
Q 11.4	What is the current role of family offices? .....	11-6
Q 11.5	What is the current role of venture capital? .....	11-7

## Table of Contents

---

Q 11.6	What is the current role of initial public offerings? .....	11-7
Q 11.7	What is the current role of M&A? .....	11-8
<b>Post-IPO Financing for Public Biotech Companies</b> .....		11-9
Q 11.8	What financing needs exist after the initial public offering? .....	11-9
Q 11.8.1	What is a follow-on offering? .....	11-9
Q 11.8.2	What is a registered direct offering? .....	11-10
Q 11.8.3	What are private investments in public equity? .....	11-10
Q 11.8.4	What are at-the-market offerings? .....	11-11
Q 11.8.5	What are committed equity financing facilities? .....	11-11
Q 11.8.6	What other forms of equity financings are used to raise capital? .....	11-11
<b>Licensing and Other Collaborations Between Pharmaceutical and Biotech Companies</b> .....		11-12
Q 11.9	Why is licensing becoming more attractive to big pharma? .....	11-12
Q 11.10	What can big pharma and biotech companies each contribute in a collaboration? .....	11-12
Q 11.11	At what stage of drug development does a collaboration take place? .....	11-13
Q 11.12	What terms can be expected in a licensing transaction? .....	11-13
Q 11.13	When are contingent value rights used? .....	11-14
<b>More Financing Alternatives</b> .....		11-14
Q 11.14	What are some alternatives to dilutive equity financing of drug development? .....	11-14
Q 11.14.1	What is venture lending? .....	11-14
Q 11.14.2	What are royalty-based financings? .....	11-15
Q 11.14.3	What are financings linked to clinical research organizations? .....	11-15
Q 11.14.4	What are structured drug development financings? .....	11-16

## Chapter 12 Financing of Health Care M&A Transactions

*Jeffrey E. Ross, Scott B. Selinger & Bradley K. Waldstreicher*

<b>Acquisition Financing Generally</b> .....		12-2
Q 12.1	What are the different types of acquisition financing? .....	12-2
Q 12.1.1	What is cash-flow financing and how is it used in acquisition financing? .....	12-3
Q 12.1.2	What is asset-based financing and how is it used in acquisition financing? .....	12-4

## HEALTH CARE MERGERS & ACQUISITIONS AB

---

<b>Acquisition Financing in the Health Care Industry</b> .....	12-5
Q 12.2 What are typical financing concerns when financing the acquisition of a target in the health care industry? .....	12-5
Q 12.3 Why is the “corporate practice of medicine” doctrine relevant to acquisition financing? .....	12-6
Q 12.4 How does HIPAA affect the due diligence process, inspection rights, enforcement rights, and control mechanisms of a lender? .....	12-7
Q 12.4.1 Is it possible to avoid having HIPAA apply to a financing? .....	12-9
Q 12.4.2 What impact does HIPAA have on telehealth?.....	12-9
Q 12.5 What are typical asset-based financing issues in the health care industry? .....	12-10
Q 12.5.1 What is a borrowing base? .....	12-10
Q 12.5.2 What is the typical payor mix in the borrowing base of a borrower in the health care industry? .....	12-11
Q 12.5.3 What are Medicare and Medicaid? .....	12-12
Q 12.5.4 How does the payor mix affect collectability of accounts receivable and, in turn, the borrowing base? .....	12-12
Q 12.5.5 Why do gross and net health care receivable amounts differ substantially? .....	12-13
Q 12.5.6 What protections are built into the borrowing base against deterioration of the health care business?.....	12-15
Q 12.5.7 What issues are associated with lending against inventory in the health care industry? .....	12-15
Q 12.6 How predictable is the cash flow of a health care business and how is it relevant for financing? .....	12-16
Q 12.6.1 What are setoff rights?.....	12-16
Q 12.6.2 What is the true-up process? .....	12-17
Q 12.7 How does a lender perfect a security interest in government receivables such as Medicare and Medicaid receivables?.....	12-18
Q 12.7.1 What is Article 9 of the Uniform Commercial Code? .....	12-19
Q 12.7.2 How does Article 9 apply to government receivables?.....	12-19
Q 12.7.3 What are Medicare and Medicaid anti-assignment laws?.....	12-20
Q 12.7.4 How do anti-assignment laws affect acquisition financing in the health care industry?.....	12-21
Q 12.7.5 What is a double lockbox structure? .....	12-23
Q 12.7.6 Does the double lockbox structure provide complete control to the lender? .....	12-23
Q 12.8 What other enforcement risks do lenders face? .....	12-24

## Chapter 13 Tax Considerations

*Peter A. Furci, Michael Bolotin, Samuel D. Krawiecz &  
Olivia Coral Daniels*

<b>Tax Consequences of Acquiring Publicly Traded Target Shares for Cash and CVRs</b> .....	13-2
<i>Open Transactions</i> .....	13-2
Q 13.1 What is the open transaction doctrine? .....	13-2
Q 13.2 Is open transaction reporting available in connection with the issuance of CVRs in a corporate acquisition? .....	13-2
Q 13.3 What is the tax treatment of shareholders who receive CVRs in an open transaction? .....	13-3
Q 13.4 Is the open transaction doctrine always favorable to the taxpayer? .....	13-3
<i>Closed Transactions</i> .....	13-4
Q 13.5 What is the closed transaction doctrine? .....	13-4
Q 13.6 What is the tax treatment of shareholders who receive CVRs in a closed transaction? .....	13-4
Q 13.7 How are CVRs valued for closed transaction purposes? .....	13-5
Q 13.8 Can the installment sale method of reporting be used in connection with the receipt of a CVR? .....	13-5
<i>Other Issues</i> .....	13-6
Q 13.9 What special tax issues may arise when CVRs are issued to non-U.S. persons? .....	13-6
Q 13.10 Can a CVR that only pays in shares of the issuer be received free of tax in a corporate reorganization? .....	13-6

## Chapter 14 Accounting Considerations

*John M. (Chip) Clark III, John L. Babitt & Peter Hornecker*

<b>Relevant Guidance</b> .....	14-3
<b>Key Terms</b> .....	14-4
<b>Business Combinations and Asset Acquisitions</b> .....	14-6
<i>Acquisition Method</i> .....	14-6
Q 14.1 Under what circumstances does the acquisition method of accounting apply? .....	14-6

## HEALTH CARE MERGERS & ACQUISITIONS AB

---

Q 14.2	How does the acquirer determine whether a transaction is considered a business combination? .....	14-7
Q 14.3	What are the accounting considerations in assessing the valuation of the balance sheet? .....	14-12
Q 14.4	What is pushdown accounting and when can it be applied?.....	14-13
Q 14.5	What are the fair value measurement considerations an acquirer should consider and what are the exceptions? .....	14-13
Q 14.6	In general, how should R&D costs be treated in financial statements? .....	14-15
Q 14.7	How does the acquisition method of accounting impact research and development assets? .....	14-16
Q 14.8	What is the subsequent accounting for IPR&D acquired in a business combination?.....	14-17
Q 14.9	How does the acquisition method of accounting impact inventory? .....	14-17
Q 14.10	What are considerations in a business combination when an acquirer has a preexisting relationship with the target? .....	14-18
Q 14.11	How do amendments to ASC 805 improve accounting for acquired revenue contracts with customers in a business combination? .....	14-19
Q 14.12	How does the acquisition method of accounting impact leases?.....	14-21
Q 14.13	How should an acquirer assess other executory contracts acquired?.....	14-22
<b>Unique Change in Control Considerations</b> .....		14-22
Q 14.14	What change-in-control considerations are there with respect to share-based compensation?.....	14-22
Q 14.15	What change-in-control considerations are there with respect to employment contracts? .....	14-23
Q 14.16	What change-in-control considerations are raised by debt and financing or other agreements? .....	14-24
Q 14.17	What change-in-control considerations are specific to joint ventures and alliances? .....	14-24
Q 14.18	What change-in-control considerations are raised by licenses and service contracts? .....	14-24
<b>Business Combination Concepts</b> .....		14-25
Q 14.19	What is consideration transferred? .....	14-25
Q 14.20	When are earnouts used in acquisitions and what are the accounting implications? .....	14-27

## Table of Contents

---

Q 14.21	What are the SEC reporting requirements for public companies in connection with significant acquisitions? .....	14-28
Q 14.22	What tests are used to determine whether an acquisition is considered to be a significant subsidiary? .....	14-30
Q 14.23	What are the timing requirements for filing? .....	14-31
Q 14.24	What are the general rules and requirements of Article 11 pro formas and what is their purpose? .....	14-32
Q 14.25	What are the general rules and requirements for pro forma balance sheets?.....	14-32
Q 14.26	What are the general rules and requirements for pro forma income statements?.....	14-33
Q 14.27	What should an acquirer consider regarding acquired patient receivables? .....	14-33
Q 14.28	What should an acquirer consider regarding reconsideration of segment reporting conclusions? .....	14-34
<b>Common Diligence Considerations</b> .....		14-35
<i>EBITDA</i> .....		14-35
Q 14.29	What is EBITDA and how does it impact valuation?.....	14-35
Q 14.30	What are common derivatives of EBITDA? .....	14-37
Q 14.31	What is Management EBITDA? .....	14-39
Q 14.32	What considerations are unique to the health care industry and result in financial statement risk?.....	14-40
Q 14.33	What are typical health care EBITDA adjustments? .....	14-42
<b>Revenue Recognition</b> .....		14-43
Q 14.34	What are the primary considerations with respect to proper revenue recognition? .....	14-43
Q 14.35	What are some other revenue items to consider as part of the health care revenue cycle? .....	14-46
Q 14.36	What are the gross-to-net revenue reconciling items impacting revenue recognition in health care services companies? .....	14-47
Q 14.37	What are the gross-to-net-revenue adjustments impacting revenue recognition in life sciences companies?.....	14-49
Q 14.38	How are product returns handled? .....	14-50
Q 14.39	How are chargebacks handled? .....	14-51
Q 14.40	What is the potential impact of the new revenue recognition standard on life sciences transactions? .....	14-51

## HEALTH CARE MERGERS & ACQUISITIONS AB

---

Q 14.41	What is the potential impact on collaboration arrangements? .....	14-52
Q 14.42	What is the potential impact on estimating variable consideration? .....	14-53
Q 14.43	What is the potential impact on reseller and distributor arrangements? .....	14-55
Q 14.44	What is the potential impact on licenses of intellectual property? .....	14-56
Q 14.45	What are the general revenue recognition considerations related to research and development arrangements between life sciences entities? .....	14-57
Q 14.46	How can one determine the substance of a R&D arrangement? .....	14-59
Q 14.47	What are the accounting considerations for R&D arrangements from the point of view of the entities involved? .....	14-62
Q 14.48	How are collaborations or arrangements to perform R&D services that are not financing arrangements accounted for? .....	14-64
Q 14.49	How should up-front fees be recognized for R&D activity? .....	14-67
Q 14.50	What are common considerations for contracts with multiple performance obligations? .....	14-68
Q 14.51	What are important revenue recognition issues related to intellectual property licensing? .....	14-69
<b>Balance Sheet Considerations</b> .....		14-70
Q 14.52	What balance sheet considerations are particularly important during due diligence? .....	14-70
Q 14.53	What balance sheet considerations are unique to the health care industry? .....	14-71
Q 14.54	How will the new credit impairment standard affect a target company's periodic assessment of credit losses for most financial assets that may impact the expected margin and equity? .....	14-72
Q 14.55	What are medical claims liabilities? .....	14-74
Q 14.56	What risks arise in analyzing medical malpractice, workers' compensation, and other self-insured claims? .....	14-74
Q 14.57	What are key considerations with respect to product warranties with life sciences companies? .....	14-75

## Table of Contents

---

Q 14.58	What other liabilities should be considered in conducting due diligence of health care entities? .....	14-76
Q 14.59	What are restructuring reserves and expenses?.....	14-77
<b>Commitments and Contingencies</b> .....		14-78
Q 14.60	What are commitments and contingencies?.....	14-78
Q 14.60.1	How are commitments and contingencies quantified?.....	14-78
Q 14.61	What types of commitments and contingencies are common in health care services entities? .....	14-79
Q 14.61.1	What risks relate to managed care agreements with employers or subcontract agreements with payors? .....	14-80
Q 14.61.2	What risks relate to physician guarantees?.....	14-80
<b>Risk-Based Capital</b> .....		14-80
Q 14.62	What is risk-based capital? .....	14-80
Q 14.63	What is statutory net worth?.....	14-81
Q 14.64	How does SAP accounting impact statutory net worth?.....	14-81
Q 14.65	What calculations are typically used to assess the adequacy of an insurer's statutory net worth? .....	14-82
Q 14.65.1	What measure do most advisors use to assess an insurer's statutory net worth?.....	14-82
Q 14.66	How are the insurer's RBC ratio and authorized control level calculated? .....	14-83
Q 14.67	Why are RBC and statutory net worth relevant in health care M&A? .....	14-83
<b>Other Bank Requirements</b> .....		14-84
Q 14.68	What should I consider in negotiating bank covenants? .....	14-84
Q 14.69	What are reasonable financial reporting requirements?.....	14-85
Q 14.70	What is minimum working capital? .....	14-86

**PART II**  
**DUE DILIGENCE**

**Chapter 15 Introduction to Due Diligence in Health Care  
M&A Transactions**

*Andrew L. Bab, Kim T. Le & Hannah R. Levine*

<b>Due Diligence Generally</b> .....	15-3
Q 15.1 Why is due diligence important?.....	15-3
Q 15.2 When is due diligence conducted? .....	15-4
<b>Due Diligence in Health Care Deals</b> .....	15-5
Q 15.3 What is the proper scope of health care M&A due diligence?.....	15-5
Q 15.4 What are the key areas of health care M&A due diligence?.....	15-7
Q 15.5 Who are the key parties and how are due diligence responsibilities typically allocated? .....	15-8

**Chapter 16 Product Development and Marketing**

*Paul D. Rubin, Melissa B. Runsten, Zoe J. Jacoby &  
Kaitlyn E. McGill*

<b>Definitions</b> .....	16-2
Q 16.1 What is a “drug” under the Federal Food, Drug, and Cosmetic Act? .....	16-2
Q 16.2 What is a “new drug”?.....	16-3
Q 16.3 What is a “biologic”? .....	16-4
Q 16.4 What is a “medical device”?.....	16-4
Q 16.4.1 Is software considered a medical device?.....	16-5
Q 16.4.2 What is a “combination product”? .....	16-6
Q 16.5 What categories of medical devices are regulated by FDA? .....	16-7
Q 16.5.1 What is a Class I medical device?.....	16-9
Q 16.5.2 What is a Class II medical device?.....	16-10
Q 16.5.3 What is a Class III medical device?.....	16-11
Q 16.5.4 What is an Emergency Use Authorization (EUA)?.....	16-11

## Table of Contents

---

<b>Preclinical Testing</b> .....	16-12
Q 16.6 What is preclinical testing and why is it conducted? .....	16-12
Q 16.7 What types of preclinical tests must be completed before engaging in clinical testing in humans? .....	16-12
Q 16.8 What are good laboratory practices for preclinical testing? .....	16-13
<b>Clinical Studies: The IND and IDE Processes</b> .....	16-15
Q 16.9 What are clinical studies? .....	16-15
Q 16.10 What are the clinical trial registry requirements? .....	16-16
Q 16.11 What is the Investigational New Drug process? .....	16-16
Q 16.11.1 What is a “sponsor” of an IND? .....	16-17
Q 16.11.2 What are an IND sponsor’s responsibilities? .....	16-17
Q 16.12 What is an Investigational Device Exemption? .....	16-19
Q 16.13 What device studies do not require an IDE? .....	16-20
Q 16.14 What device studies require an IDE? .....	16-21
Q 16.14.1 What is the procedure for investigational devices that present nonsignificant risks? .....	16-21
Q 16.14.2 What is the procedure for investigational devices that present significant risks? .....	16-21
Q 16.15 What phases of clinical studies are conducted during the IND process? .....	16-22
Q 16.16 What is an institutional review board (IRB)? .....	16-24
<b>Clinical Studies: Good Clinical Practice Requirements</b> .....	16-25
Q 16.17 What are FDA’s good clinical practice (GCP) requirements? .....	16-25
Q 16.18 What are the requirements for obtaining informed consent from study subjects? .....	16-26
Q 16.18.1 What information must be provided to subjects? .....	16-26
Q 16.18.2 Are there exceptions to the informed consent requirements? .....	16-28
Q 16.19 What financial disclosures must be made by clinical investigators? .....	16-29
Q 16.19.1 What must be included in FDA Form 3455? .....	16-30
Q 16.19.2 What must be included in FDA Form 3454? .....	16-30
Q 16.19.3 What can FDA do if it has concerns about an investigator’s financial bias? .....	16-31
Q 16.19.4 What are decentralized clinical trials? .....	16-31
Q 16.19.5 What are adaptive clinical trials? .....	16-31

## HEALTH CARE MERGERS & ACQUISITIONS AB

---

<b>Other FDA Powers</b> .....	16-32
Q 16.20 With regard to clinical studies, what inspection rights does FDA have?.....	16-32
Q 16.21 What is an FDA clinical hold? .....	16-33
<b>Applications to FDA</b> .....	16-33
Q 16.22 What is a New Drug Application? .....	16-33
Q 16.23 What is an Abbreviated New Drug Application? .....	16-34
Q 16.24 What is a 505(b)(2) NDA? .....	16-34
Q 16.25 What is a biologics license application (BLA)? .....	16-36
Q 16.26 Is there an approval process for generic or “follow-on” biologics?.....	16-36
Q 16.27 What is a device premarket approval application?.....	16-36
Q 16.28 What is a device 510(k) clearance? .....	16-37
Q 16.28.1 What is an abbreviated 510(k)? .....	16-38
Q 16.28.2 What is a special 510(k)?.....	16-39
Q 16.29 What is a De Novo classification request? .....	16-39
Q 16.30 Can any medical devices be marketed without prior FDA review or approval?.....	16-40
<b>Application Fees</b> .....	16-40
Q 16.31 What diligence is needed regarding payment of application fees to FDA? .....	16-40
Q 16.32 What are drug user fee laws? .....	16-40
Q 16.32.1 Can companies obtain a waiver of PDUFA user fees?.....	16-42
Q 16.32.2 Can “small” companies obtain a waiver of PDUFA user fees?.....	16-42
Q 16.33 What is the Medical Device User Fee and Modernization Act? .....	16-43
Q 16.33.1 Can companies obtain a waiver of MDUFMA user fees?.....	16-44
Q 16.34 What is the Biosimilar User Fee Act?.....	16-44
<b>Assessing the Target’s Regulatory Basis for Marketing Regulated Products</b> .....	16-45
Q 16.35 What are basic diligence issues regarding the target’s marketing of drug, biologic, and medical device products?.....	16-45
Q 16.36 What is FDA’s over-the-counter drug review process? .....	16-46
Q 16.37 What if the target produces homeopathic drugs? .....	16-49

## Table of Contents

---

Q 16.38	What issues are raised by unapproved drugs? .....	16-50
Q 16.39	What issues are raised by 510(k) clearances?.....	16-52
Q 16.40	What issues are raised by medical devices marketed without prior FDA review or approval? .....	16-53
Q 16.41	What issues are raised by modifications to a drug, device, or biologic that has been approved or cleared by FDA?.....	16-54
Q 16.42	What issues are raised by promotion of drugs limited to certain indications?.....	16-55
Q 16.43	What issues are raised by drug approval limited to specific patient populations? .....	16-56
Q 16.44	What other limitations may be placed on a product by the terms of its approval or clearance? .....	16-56
<b>Other Product Development Issues</b> .....		16-57
Q 16.45	How does FDA regulate artificial intelligence (AI) in medical device and drug development?.....	16-57
Q 16.46	How does FDA expect medical device manufacturers to address cybersecurity during the development process?.....	16-58
<b>Patient Access to Investigational Products</b> .....		16-59
Q 16.47	What is FDA's expanded access program?.....	16-59
Q 16.48	How does the Right to Try Act affect patient access?.....	16-59
<b>Postapproval Requirements</b> .....		16-60
Q 16.49	What are postapproval requirements for approved or cleared products?.....	16-60
Q 16.50	What types of postapproval requirements can FDA impose on drug products? .....	16-61
Q 16.50.1	What NDA and ANDA supplements may be required? .....	16-61
Q 16.50.2	What annual reports may be required?.....	16-62
Q 16.50.3	What postmarket studies may be required?.....	16-62
Q 16.51	What types of postapproval requirements can FDA impose on medical devices? .....	16-63
Q 16.51.1	What PMA supplements may be required?.....	16-64
Q 16.51.2	What annual reports may be required?.....	16-64
Q 16.51.3	What postmarket studies may be required?.....	16-64
Q 16.51.4	What general postapproval requirements may be imposed? .....	16-65
Q 16.52	How does FDA regulate the postmarket surveillance of medical device cybersecurity?.....	16-66

## Chapter 17 Patent Extensions and Market Exclusivities

*Paul D. Rubin, Melissa B. Runsten & Carey B. Nuttall*

<b>Summary of Incentives</b> .....	17-2
Q 17.1 What are the chief ways in which the law creates incentives for drug development and competition?.....	17-2
<b>Extensions of Patent Term</b> .....	17-6
Q 17.2 What are the available statutory patent term extensions?.....	17-6
<b>Exclusivities</b> .....	17-7
Q 17.3 What is five-year “new chemical entity” exclusivity under the Hatch-Waxman Act?.....	17-7
Q 17.4 What is three-year exclusivity under the Hatch-Waxman Act?.....	17-8
Q 17.5 What is seven-year orphan drug exclusivity?.....	17-8
Q 17.6 What is six-month pediatric exclusivity?.....	17-9
Q 17.7 What is five-year Qualified Infectious Disease Product (QIDP) exclusivity?.....	17-9
Q 17.8 What is innovator product exclusivity for biologic products?.....	17-10
Q 17.9 What are 180-day generic drug exclusivity, follow-on biologic exclusivity, and the thirty-month stay of generic drug approval?.....	17-11
Q 17.10 What is competitive generic therapy exclusivity?.....	17-12
Q 17.11 What is eighteen-month OTC drug exclusivity?.....	17-12

## Chapter 18 Manufacturing and Distribution Requirements

*Paul D. Rubin, Melissa B. Runsten, Anne D. Spiggle,  
Zoe J. Jacoby & Kaitlyn E. McGill*

<b>Good Manufacturing Practices</b> .....	18-2
Q 18.1 What are FDA’s good manufacturing practice requirements for drugs?.....	18-2
Q 18.2 What are FDA’s quality system regulations?.....	18-3
Q 18.3 Can FDA inspect the premises of drug, biologic, and device manufacturers?.....	18-3
Q 18.4 What due diligence is appropriate regarding current good manufacturing practices?.....	18-4

## Table of Contents

---

<b>Standard Operating Procedures</b> .....	18-5
Q 18.5 What are “standard operating procedures” for drug, device, and biologic operations? .....	18-5
Q 18.6 What types of operations should be supported by written SOPs? .....	18-5
Q 18.7 What are the benefits of maintaining standard operating procedures?.....	18-6
Q 18.8 What due diligence should be conducted regarding the target’s standard operating procedures? .....	18-6
<b>Systems for Handling Reports of Failures or Malfunctions</b> .....	18-7
Q 18.9 What systems should a company have for responding to product failures or malfunctions? .....	18-7
Q 18.10 What are “corrective and preventive action” requirements generally? .....	18-7
Q 18.11 What are the CAPA requirements for medical devices? .....	18-8
Q 18.12 What are the CAPA requirements for drugs and biologics?.....	18-9
Q 18.13 What due diligence should be conducted regarding the target’s CAPA systems?.....	18-9
<b>Contract Manufacturers</b> .....	18-11
Q 18.14 What role do contract manufacturers play in the industry? ....	18-11
Q 18.15 What are the respective responsibilities of contract manufacturers and entities holding FDA approvals or clearances?.....	18-11
Q 18.16 What due diligence should be conducted regarding the target’s use of contract manufacturers?.....	18-12
<b>Establishment Registration, Product Listing, and Requirements for Bulk Active Pharmaceutical Ingredients</b> .....	18-12
Q 18.17 What are FDA registration requirements for drug and device establishments? .....	18-12
Q 18.18 What due diligence should be conducted regarding registration issues? .....	18-13
Q 18.19 What are FDA listing requirements for drugs and devices?.....	18-14
Q 18.20 What due diligence should be conducted regarding listing issues?.....	18-14
Q 18.21 What are the requirements for bulk active pharmaceutical ingredients?.....	18-15
Q 18.22 What due diligence should be conducted regarding bulk active pharmaceutical ingredients? .....	18-15

<b>Distribution of Prescription Drugs and Medical Devices</b> .....	18-16
Q 18.23 What is the closed drug distribution system?.....	18-16
Q 18.24 What is the Drug Supply Chain Security Act?.....	18-16
Q 18.25 What is the Prescription Drug Marketing Act?.....	18-17
Q 18.26 What are licensed drug distributors?.....	18-17
Q 18.27 What is the medical device unique device identification (UDI) System? .....	18-18
<b>State Licensing Requirements</b> .....	18-18
Q 18.28 Do the states require licenses to manufacture, repackage, or distribute drugs, biologics, or medical devices?.....	18-18
Q 18.29 What due diligence should be conducted regarding the target's state law licensing?.....	18-19

## Chapter 19 FDA Investigations and Enforcement

*Paul D. Rubin, Melissa B. Runsten & Anne D. Spiggle*

<b>Inspections</b> .....	19-2
Q 19.1 What is an FDA inspection?.....	19-2
Q 19.2 What is FDA Form 483?.....	19-3
Q 19.2.1 Must a company respond to a Form 483?.....	19-3
Q 19.2.2 What is the significance of Form 483 for due diligence?.....	19-3
Q 19.3 How does FDA classify inspection results?.....	19-4
Q 19.4 What is an establishment inspection report?.....	19-4
Q 19.5 Where can official information about past inspections be found? .....	19-5
Q 19.6 What other inspection-related communications with FDA are relevant to due diligence?.....	19-5
Q 19.7 Does FDA have the authority to request records in advance of an inspection, and does FDA perform remote or virtual facility assessments? .....	19-6
<b>Enforcement Mechanisms</b> .....	19-6
Q 19.8 What is FDA's general enforcement authority?.....	19-6
Q 19.9 What is a warning letter?.....	19-7
Q 19.10 What is an untitled letter?.....	19-8

## Table of Contents

---

Q 19.11	What is a seizure?.....	19-8
Q 19.12	What is an injunction? .....	19-9
Q 19.13	What is an FDA consent decree? .....	19-10
Q 19.14	What criminal penalties are available under the FFDCA? .....	19-10
Q 19.15	What civil monetary penalties are available under the FFDCA?.....	19-11
Q 19.16	What are disqualification and debarment? .....	19-11
Q 19.17	What are due diligence considerations regarding corrective actions in response to FDA enforcement?.....	19-12
<b>Product Recalls and Market Withdrawals .....</b>		<b>19-12</b>
Q 19.18	What are product recalls? .....	19-12
Q 19.19	How does FDA classify recalls? .....	19-12
Q 19.20	What are “voluntary” recalls?.....	19-13
Q 19.20.1	What are FDA-requested recalls? .....	19-14
Q 19.20.2	What information must be provided to FDA if a company initiates a recall? .....	19-14
Q 19.21	When can FDA recall medical devices? .....	19-15
Q 19.22	When can FDA recall biological products? .....	19-16
Q 19.23	What is a market withdrawal? .....	19-16
Q 19.24	What is a stock recovery? .....	19-16
<b>Reporting Adverse Events .....</b>		<b>19-16</b>
Q 19.25	What is an adverse drug event? .....	19-16
Q 19.26	How does a company find out about adverse events involving its drugs? .....	19-17
Q 19.27	What is an adverse event report? .....	19-17
Q 19.28	Is adverse event reporting required for nonprescription, over-the-counter drugs?.....	19-18
Q 19.29	Is adverse event reporting required for medical devices?.....	19-19
Q 19.29.1	What MDR event reports must be made by user facilities?.....	19-19
Q 19.29.2	What MDR event reports must be made by manufacturers?.....	19-19
Q 19.30	What systems should a company have for responding to and reporting adverse drug events? .....	19-20
Q 19.31	What systems should a company have for responding to and reporting adverse medical device events?.....	19-21

**Chapter 20 Promotion and Advertising**

*Paul D. Rubin, Melissa B. Runsten, Zoe J. Jacoby & Kaitlyn E. McGill*

**General Principles**.....20-2

Q 20.1 What are the fundamental requirements for drug promotion and advertising?.....20-2

Q 20.2 How do FDA and FTC share regulation of drug advertising?.....20-2

**FDA Regulation of Drug Promotion and Advertising**.....20-3

Q 20.3 What are advertising and promotional labeling? .....20-3

Q 20.4 What is “off-label” promotion?.....20-3

Q 20.5 What is risk information and how is it to be disclosed? .....20-5

Q 20.6 What else can cause drug promotion to be considered misleading?.....20-6

Q 20.7 What are the rules for direct-to-consumer advertising? .....20-7

Q 20.8 What is drug preapproval promotion? .....20-7

Q 20.9 Must promotional materials be submitted to or approved by FDA? .....20-8

Q 20.10 What is the Office of Prescription Drug Promotion? .....20-8

Q 20.11 Has FDA issued guidance documents addressing drug promotion and advertising?.....20-9

Q 20.12 Can drug or device companies challenge claims made in competitor advertising? .....20-10

**FDA Regulation of Device Marketing and Advertising**.....20-11

Q 20.13 How does FDA regulate device marketing and advertising?.....20-11

**FTC Advertising Requirements** .....20-12

Q 20.14 How do the FTC and FDA work together to regulate drug and device promotion?.....20-12

Q 20.15 What are the basic principles of FTC advertising regulation?.....20-12

Q 20.16 Has the FTC issued guidance addressing health products promotion and advertising?.....20-13

## Chapter 21 Compliance with Import and Export Requirements

*Paul D. Rubin, Melissa B. Runsten & Eric T. Rasmussen*

<b>FDA Import Regulation</b> .....	21-2
Q 21.1 What is FDA's general authority over imports?.....	21-2
Q 21.2 How is responsibility for imports shared by FDA and Customs and Border Protection?.....	21-2
Q 21.3 How does FDA become aware of an import subject to its authority?.....	21-2
Q 21.4 What initial steps does FDA take to determine if an imported article violates the law?.....	21-3
Q 21.5 What is the procedure when no violation is found?.....	21-3
Q 21.6 What is the procedure when a violation is found?.....	21-3
Q 21.7 What if the imported article is intended for export from the United States?.....	21-5
Q 21.8 What is FDA's authority to refuse imports under the "appears-to-be-violative" standard?.....	21-5
Q 21.9 What are FDA import alerts?.....	21-6
Q 21.10 How does FDA regulate the importing of active pharmaceutical ingredients?.....	21-7
<b>FDA Export Regulation</b> .....	21-7
Q 21.11 What are FDA requirements to export a product produced in compliance with the FFDCRA?.....	21-7
Q 21.12 Can adulterated or misbranded products be exported?.....	21-8
Q 21.12.1 How can a company establish that a product meets the specifications of a foreign purchaser?.....	21-8
Q 21.12.2 How can a company establish that a product does not conflict with the laws of the importing country?.....	21-9
Q 21.12.3 How can a company satisfy the labeling requirement?.....	21-10
Q 21.12.4 How can a company show that the product is not sold or offered for sale in the United States?.....	21-10
Q 21.13 Can unapproved drugs, biological products, and devices be exported?.....	21-11
Q 21.13.1 What are the basic export requirements for unapproved drugs, biological products, and devices?.....	21-12

Q 21.13.2	What are the additional requirements to export unapproved drugs, biological products, and devices to a listed country? .....	21-13
Q 21.13.3	What are the additional requirements to export unapproved new drugs, biological products, and devices, to an unlisted country? .....	21-15

## **Chapter 22 Miscellaneous Communications with FDA**

*Paul D. Rubin, Melissa B. Runsten, & Anne D. Spiggle*

<b>Comments and Petitions</b> .....	22-2	
Q 22.1	When does FDA solicit comments regarding rulemakings, guidance documents, or other topics?.....	22-2
Q 22.2	What is a Citizen Petition to FDA?.....	22-2
Q 22.3	How is FDA addressing misuse of Citizen Petitions? .....	22-3
<b>Other Communications</b> .....	22-4	
Q 22.4	What other formal or informal communications with FDA should be investigated?.....	22-4

## **Chapter 23 Compliance with DEA Controlled Substance Requirements**

*Paul D. Rubin, Melissa B. Runsten & Eric T. Rasmussen*

<b>Scheduled Drugs</b> .....	23-2	
Q 23.1	What are the general consequences of scheduling a drug as a controlled substance?.....	23-2
Q 23.2	What are the five schedules of controlled substances? .....	23-3
Q 23.3	What is the process by which drug substances are scheduled?.....	23-3
<b>Registration</b> .....	23-4	
Q 23.4	Who must register with the DEA? .....	23-4
<b>Quotas</b> .....	23-5	
Q 23.5	What are DEA's manufacturing and procurement quotas for controlled substances?.....	23-5

## Table of Contents

---

<b>Security</b> .....	23-5
Q 23.6 What are the general requirements for security in storing and handling controlled substances?.....	23-5
Q 23.7 What factors does DEA consider in evaluating whether a company has good security regarding controlled substances? .....	23-6
Q 23.8 What are the storage requirements for controlled substances? .....	23-7
Q 23.9 How are manufacturing processes regulated? .....	23-7
Q 23.10 What are the security requirements for distribution and shipping? .....	23-8
<b>Recordkeeping and Reporting</b> .....	23-8
Q 23.11 What records must be kept by those working with controlled substances?.....	23-8
Q 23.12 What reporting obligations do registrants have?.....	23-9
<b>Inspections and Enforcement Actions</b> .....	23-9
Q 23.13 What are DEA’s inspection powers?.....	23-9
Q 23.14 When does DEA need a warrant to make an inspection?.....	23-10
Q 23.15 How often do inspections occur?.....	23-11
Q 23.16 What administrative enforcement actions can the DEA pursue?.....	23-11
Q 23.17 Can the DEA seek monetary penalties?.....	23-12
Q 23.18 Can the DEA seek criminal penalties?.....	23-12
Q 23.19 Has the DEA pursued enforcement actions targeted at the ongoing opioid crisis?.....	23-12
<b>Chapter 24 Compliance with Federal and State Health Care Fraud and Abuse Laws</b>	
<i>Kim T. Le, Hannah R. Levine, Michael L. Cederblom &amp; Kaitlyn E. McGill</i>	
<b>The Anti-Kickback Statute</b> .....	24-4
Q 24.1 What is the Anti-Kickback Statute? .....	24-4
Q 24.2 What kinds of payment are prohibited? .....	24-4
Q 24.3 What level of knowledge and intent is required? .....	24-6
Q 24.4 To whom does the Anti-Kickback Statute apply? .....	24-7
Q 24.5 To what types of goods and services does the Anti-Kickback Statute apply? .....	24-7

## HEALTH CARE MERGERS & ACQUISITIONS AB

---

Q 24.6	What is a “federal health care program”?	24-8
Q 24.7	Are there any statutory safe harbors?	24-8
Q 24.8	Are there any regulatory safe harbors?	24-10
Q 24.9	What criteria must be satisfied for a payment to fall within a safe harbor?	24-12
Q 24.10	What are the potential direct consequences of an anti-kickback violation?	24-13
Q 24.11	What are the potential collateral consequences of an anti-kickback violation?	24-14
Q 24.12	What due diligence is appropriate regarding anti-kickback issues?	24-15
<b>The Stark Law</b>		24-17
Q 24.13	What is the Stark law?	24-17
Q 24.14	What intent is required for a violation of the Stark law?	24-18
Q 24.15	What are the differences between the Stark law and the Anti-Kickback Statute?	24-19
Q 24.16	To what services does the Stark law apply?	24-20
Q 24.17	What is a “referral” for purposes of the Stark law?	24-21
Q 24.18	Are there any exceptions to the Stark law?	24-22
Q 24.18.1	What is the hospital-ownership exception?	24-24
Q 24.18.2	What is the personal-services exception?	24-24
Q 24.19	What are the potential direct consequences of a Stark law violation?	24-25
Q 24.20	What are the potential collateral consequences of a Stark law violation?	24-26
Q 24.21	What due diligence is appropriate regarding Stark law issues?	24-26
<b>The False Claims Act</b>		24-27
Q 24.22	What is the False Claims Act?	24-27
Q 24.23	What is a “claim”?	24-28
Q 24.24	What are “false or fraudulent” claims?	24-28
Q 24.25	What level of knowledge or intent is required?	24-30
Q 24.26	Who is liable for the submission of false or fraudulent claims?	24-30
Q 24.27	What are the potential consequences of a False Claims Act violation?	24-30
Q 24.28	What are the qui tam provisions?	24-31
Q 24.28.1	What is the relator’s share?	24-32

## Table of Contents

---

Q 24.29	Are there state false claims statutes? .....	24-32
Q 24.30	What due diligence is appropriate regarding False Claims Act issues? .....	24-33
<b>Criminal Offenses</b> .....		<b>24-34</b>
Q 24.31	What is criminal “health care fraud”? .....	24-34
Q 24.32	To what services does the health care fraud statute apply? .....	24-35
Q 24.33	What is a “health care benefit program”? .....	24-35
Q 24.34	How does the fraud statute differ from the Anti-Kickback Statute and Stark law? .....	24-35
Q 24.35	To whom does the health care fraud statute apply? .....	24-36
Q 24.36	What is a criminal conspiracy, and why might conspiracy charges be useful to prosecutors in health care fraud cases? .....	24-36
Q 24.37	What level of knowledge and intent is required for a violation of the health care fraud statute? .....	24-37
Q 24.38	Is the fraud victim’s lack of care a defense? .....	24-37
Q 24.39	What are the potential direct consequences of a health care fraud violation? .....	24-38
Q 24.40	What are the potential collateral consequences of a health care fraud violation? .....	24-38
Q 24.41	What due diligence is appropriate regarding criminal health care fraud issues? .....	24-39
<b>State Criminal Health Care Fraud and Abuse Statutes</b> .....		<b>24-39</b>
Q 24.42	Are there state criminal health care fraud and abuse statutes? .....	24-39
Q 24.43	What are state “corporate practice of medicine” laws? .....	24-40
Q 24.44	What are the potential consequences for a violation of corporate practice of medicine laws? .....	24-41
<b>Compliance Programs</b> .....		<b>24-41</b>
Q 24.45	What is a compliance program and why is it important? .....	24-41
Q 24.46	What are the duties of a chief compliance officer? .....	24-42
Q 24.47	What should you expect to see in a compliance program? .....	24-42
Q 24.48	How should a compliance program be structured? .....	24-43
Q 24.49	What is the relevance of the U.S. Sentencing Guidelines to compliance programs? .....	24-43
Q 24.50	What other guidance is available from the government? .....	24-44
Q 24.51	What is a corporate integrity agreement? .....	24-44
Q 24.52	What due diligence is appropriate for the target’s compliance program? .....	24-45

**Chapter 25 Regulatory Issues in Acquisitions of Health Care Facilities and Physician Practices**

*Kim T. Le, Hannah R. Levine, Michael L. Cederblom & Zoe Jacoby*

**Acquisitions of Licensed Health Care Facilities** .....25-2

Q 25.1 What are the principal health care regulatory issues likely to be implicated in the acquisition of a hospital or other type of licensed health care facility? .....25-2

Q 25.2 What state health care regulations may impact the acquisition of a licensed health care facility?.....25-4

*Transfer of the License*.....25-5

Q 25.3 What is a health care facility license?.....25-5

Q 25.4 How may the benefit of a health care facility license be “transferred” from seller to buyer? .....25-6

Q 25.5 Does a “change in control” of a licensed health care facility require prior notice and also approval?.....25-7

Q 25.6 Are there similar requirements for the Medicare and Medicaid programs?.....25-9

*Transfer of the Certificate of Need*.....25-10

Q 25.7 What is a certificate of need program?.....25-10

Q 25.8 How is the benefit of a certificate of need “transferred” from seller to buyer?.....25-11

Q 25.9 Is prior notice or approval required? .....25-12

*Other Permits and Approvals*.....25-13

Q 25.10 What other health care–related permits may require attention?.....25-13

Q 25.11 When might the host state’s attorney general become involved? .....25-13

*Medicare and Other Federal Law Issues* .....25-14

Q 25.12 What are the sources of federal health care regulation that may impact the acquisition of a licensed health care facility? .....25-14

Q 25.13 What Medicare regulations and rules may be implicated in an acquisition?.....25-15

Q 25.14 What are Provider Transaction Access Numbers and National Provider Identification Numbers? .....25-16

## Table of Contents

---

Q 25.15	What are Medicare “conditions of participation” and “conditions for coverage”?.....	25-16
Q 25.16	What approvals are required for a licensed health care facility to provide and bill for services to Medicare beneficiaries? .....	25-18
Q 25.17	How does the buyer secure the right for the acquired facility to continue to provide and bill for services to Medicare beneficiaries?.....	25-19
Q 25.18	What is a Medicare CHOW?.....	25-19
Q 25.19	How may the buyer handle regulatory risks arising from the seller’s pre-acquisition operation of the health care facility? .....	25-23
	<i>Other Federal Approvals</i> .....	25-25
Q 25.20	What approvals are required for a clinical laboratory? .....	25-25
Q 25.21	What approvals are required for a pharmacy?.....	25-25
Q 25.22	What are the requirements for accreditation and why do they matter? .....	25-27
	<b>Acquisitions of Physician Practices</b> .....	25-27
Q 25.23	What areas of state health care regulation may impact the acquisition of a physician practice?.....	25-27
	<i>Corporate Practice of Medicine</i> .....	25-28
Q 25.24	What is the corporate practice of medicine? .....	25-28
Q 25.25	What is the underlying public policy? .....	25-28
Q 25.26	Are there exceptions to CPOM prohibitions?.....	25-29
Q 25.27	How do CPOM considerations affect the transaction structure? .....	25-29
	<i>Fee-Splitting</i> .....	25-30
Q 25.28	What is fee-splitting?.....	25-30
Q 25.29	What is the public policy underlying the prohibitions?.....	25-30
Q 25.30	Are there exceptions to fee-splitting prohibitions? .....	25-30
Q 25.31	How do fee-splitting considerations affect the transaction structure? .....	25-31
	<i>Covenants Not to Compete</i> .....	25-32
Q 25.32	What is a covenant not to compete? .....	25-32
Q 25.33	What is the public policy underlying the limitations?.....	25-33
Q 25.34	In what situations is a covenant not to compete most likely to be enforceable?.....	25-33
Q 25.35	How do limitations on the use of covenants not to compete affect the transaction structure?.....	25-34

## HEALTH CARE MERGERS & ACQUISITIONS AB

---

<i>Patient Records</i> .....	25-35
Q 25.36 What limitations arise in connection with the transfer and maintenance of patient medical records? .....	25-35
<i>Medicare and Other Federal Law Issues</i> .....	25-36
Q 25.37 What are the primary sources of federal health care regulation that may impact the acquisition of a physician practice? .....	25-36
Q 25.38 What Medicare regulations may be implicated? .....	25-36
Q 25.39 What are Provider Transaction Access Numbers and National Provider Identification Numbers? .....	25-38
Q 25.40 What approvals are required in order for physicians (or their employers) to provide, and bill for, services to Medicare beneficiaries prior to closing? .....	25-38
Q 25.41 How does the buyer acquire the right for the acquired facility or practice group to continue to provide and bill for physician and NPP services to Medicare beneficiaries? .....	25-39

### **Chapter 26 Compliance with HIPAA and Other Privacy and Security Laws**

*Kim T. Le, Hannah R. Levine, & Michael L. Cederblom*

<b>Sanctions</b> .....	26-4
Q 26.1 What sanctions enforce compliance with HIPAA?.....	26-4
<b>Overview of HIPAA Coverage</b> .....	26-6
Q 26.2 What activities does HIPAA cover? .....	26-6
Q 26.3 What is a “Covered Entity”? .....	26-7
Q 26.4 What is a “hybrid entity”? .....	26-8
Q 26.5 What is a “Business Associate”?.....	26-9
<b>HIPAA Compliance</b> .....	26-11
Q 26.6 What are the core components of HIPAA compliance for Covered Entities?.....	26-11
Q 26.7 Who bears responsibility for ensuring HIPAA compliance? .....	26-12
Q 26.8 What is an internal HIPAA risk analysis? .....	26-13

## Table of Contents

---

Q 26.9	What compliance documents should a Covered Entity or Business Associate establish and maintain? .....	26-14
Q 26.10	What workforce training programs are required?.....	26-16
Q 26.11	How should the use and disclosure of PHI be monitored and tracked?.....	26-17
Q 26.12	What is the “minimum necessary” standard?.....	26-17
Q 26.13	How should an entity respond to requests from individuals to exercise their rights under HIPAA?.....	26-18
Q 26.14	What administrative, technical, and physical safeguards are required? .....	26-19
Q 26.15	How should internal and external complaints be handled? .....	26-19
<b>Impact of HITECH on HIPAA Compliance .....</b>		<b>26-20</b>
Q 26.16	How does HITECH modify compliance with HIPAA? .....	26-20
Q 26.17	What are the expanded requirements for Business Associates?.....	26-21
Q 26.18	What are HITECH’s changes to the HIPAA limitations on marketing and fundraising communications? .....	26-22
Q 26.19	What are the changes to the HIPAA “use and disclosure” regulations?.....	26-22
Q 26.20	What are the breach notification requirements? .....	26-23
Q 26.21	Has the enforcement authority granted to state attorneys general under HITECH resulted in increased HIPAA litigation?.....	26-25
Q 26.22	What is the impact of the new audit requirements? .....	26-26
<b>State Privacy and Security Laws .....</b>		<b>26-26</b>
Q 26.23	How do state privacy and security laws interact with federal law? .....	26-26
<b>Evolving Law.....</b>		<b>26-28</b>
Q 26.24	How does the evolving nature of privacy law affect a due diligence review? .....	26-28

## VOLUME 2

<b>Table of Chapters</b> .....	v
<b>Table of Contents</b> .....	ix

### Chapter 27 Litigation

*Mark P. Goodman, Kristin D. Kiehn &  
Hannah R. Levine*

<b>Purposes of Litigation Due Diligence</b> .....	27-2
Q 27.1 What is litigation due diligence? .....	27-2
Q 27.2 What is the purpose of litigation due diligence?.....	27-2
Q 27.3 What are the potential consequences of failing to conduct adequate litigation due diligence? .....	27-3
<b>Basics of Civil Litigation</b> .....	27-4
Q 27.4 What is civil litigation? .....	27-4
Q 27.5 What is a class action?.....	27-5
Q 27.6 What is a mass tort action?.....	27-5
Q 27.7 What are the potential consequences of liability in civil litigation?.....	27-6
Q 27.8 What are compensatory damages? .....	27-6
Q 27.9 What is injunctive relief? .....	27-6
Q 27.10 What are punitive damages?.....	27-6
Q 27.11 What are treble damages?.....	27-6
Q 27.12 What is an award of attorneys' fees? .....	27-7
<b>Common Lawsuits Against Health Care Companies</b> .....	27-7
Q 27.13 What is patent litigation? .....	27-7
Q 27.14 What is product liability litigation?.....	27-8
Q 27.15 What is consumer fraud litigation? .....	27-8
Q 27.16 What is securities litigation?.....	27-9
Q 27.17 What is antitrust litigation?.....	27-9
Q 27.18 What is trademark litigation?.....	27-9
Q 27.19 What is employment litigation?.....	27-10
Q 27.20 What types of contract disputes do health care companies face? .....	27-10
Q 27.21 What is insurance carrier litigation?.....	27-11

## Table of Contents

---

<b>Regulators and Regulatory Enforcement Actions</b> .....	27-11
Q 27.22 What is a regulatory enforcement action? .....	27-11
Q 27.23 What is a criminal enforcement action? .....	27-12
Q 27.24 What is a civil enforcement action? .....	27-12
Q 27.25 What are the potential consequences of a regulatory enforcement action? .....	27-12
Q 27.26 What is the role of the Food and Drug Administration? .....	27-14
Q 27.27 What is the role of the Department of Justice and U.S. Attorneys' Offices? .....	27-14
Q 27.28 What is the role of the U.S. Securities and Exchange Commission? .....	27-15
Q 27.29 What is the role of the Federal Trade Commission? .....	27-15
Q 27.30 What is the role of the Patent and Trademark Office? .....	27-15
Q 27.31 What is the role of state attorneys general in enforcing laws against health care companies? .....	27-16
Q 27.32 What is the role of licensing authorities and accreditation bodies? .....	27-16
<b>Relevant Statutes</b> .....	27-17
Q 27.33 What is the Federal Food, Drug, and Cosmetic Act? .....	27-17
Q 27.34 What is the Prescription Drug Marketing Act? .....	27-20
Q 27.35 What are securities laws? .....	27-20
Q 27.36 What are antitrust laws? .....	27-20
Q 27.37 What is medical malpractice litigation? .....	27-22
Q 27.38 What is the Stark Law? .....	27-22
Q 27.39 What are the Foreign Corrupt Practices Act and the UK Bribery Act? .....	27-23
Q 27.40 What are international trade laws? .....	27-24
<b>Health Care Fraud</b> .....	27-24
Q 27.41 What is health care fraud? .....	27-24
Q 27.42 What are federal health care programs? .....	27-25
Q 27.43 What is the role of the U.S. Department of Health and Human Services Office of Inspector General? .....	27-26
Q 27.44 What is the Anti-Kickback Statute? .....	27-26
Q 27.45 What is the False Claims Act? .....	27-27
Q 27.46 What does it mean to be excluded from federal health care programs? .....	27-29
Q 27.47 What is a corporate integrity agreement? .....	27-29

## HEALTH CARE MERGERS & ACQUISITIONS AB

---

Q 27.48	What is a corporate monitor?.....	27-30
Q 27.49	What is the Civil Monetary Penalties Law?.....	27-30
Q 27.50	What is the Health Care Fraud Statute?.....	27-31
<b>Materiality</b> .....		27-31
Q 27.51	How is the materiality of a litigation matter assessed?.....	27-31
Q 27.52	Should certain litigation matters be considered presumptively material, regardless of projected financial exposure? .....	27-32
Q 27.53	What is an indemnitor?.....	27-33
Q 27.54	What is successor liability?.....	27-33
<b>Due Diligence Inquiries, Analysis, and Reporting</b> .....		27-33
Q 27.55	What types of information should be requested?.....	27-33
Q 27.56	Which employees of the target should be interviewed?.....	27-36
Q 27.57	What basic questions should be asked? .....	27-37
Q 27.58	What is a litigation reserve?.....	27-38
Q 27.59	What is the attorney-client privilege?.....	27-38
Q 27.60	How does the attorney-client privilege become relevant during litigation due diligence? .....	27-39
Q 27.61	How should the acquiring company respond when a target raises concerns about attorney-client privilege? .....	27-39
Q 27.62	Is it ever appropriate to demand that privileged materials be turned over? .....	27-39
Q 27.63	How is the value of a potentially material litigation matter assessed?.....	27-40
Q 27.64	Once the diligence review is complete, how are findings communicated? .....	27-41
Q 27.65	What is post-closing due diligence?.....	27-42

## Chapter 28 Intellectual Property

*Lacy L. Kolo & Scott Chambers*

<b>Due Diligence Overview</b> .....		28-2
Q 28.1	What are the key intellectual property due diligence issues in health care M&A transactions? .....	28-2
<b>Patents and Patent Applications</b> .....		28-3
Q 28.2	What are patents?.....	28-3
Q 28.3	What are the parts of a patent? .....	28-4

## Table of Contents

---

Q 28.4	Do patents have cross-border effects? .....	28-5
Q 28.5	How can one determine which patents, patent applications, and inventions are included in the deal? .....	28-6
Q 28.6	How is ownership or rights in patents or applications acquired? .....	28-7
Q 28.7	What does it mean if the list of inventors is not accurate? .....	28-9
Q 28.8	What is a shop right? .....	28-9
Q 28.9	How can one confirm that the patent-holding company has full rights to the patents and applications? .....	28-10
Q 28.10	How can one confirm that the key patents are valid? .....	28-11
Q 28.11	How can one determine whether the key patents cover the technology? .....	28-14
Q 28.12	How can one determine if the technology infringes another's patent? .....	28-15
Q 28.13	How can one determine if patents remain in force? .....	28-16
Q 28.14	How does FDA exclusivity supplement patent protection for drugs? .....	28-18
Q 28.15	What is the significance of a listing in the Orange Book? .....	28-18
Q 28.16	What are continuation, divisional, and continuation-in-part patent applications? .....	28-19
Q 28.17	How can companies maximize patent terms to extend the life of their product lines? .....	28-20
Q 28.18	What procedure should a company follow regarding its records of inventions? .....	28-23
Q 28.19	What is a patent term extension? .....	28-24
<b>Trademarks</b>	.....	28-25
Q 28.20	What are trademarks? .....	28-25
Q 28.21	How can a company protect its trademarks and service marks? .....	28-26
Q 28.22	Why are names important to branded pharmaceuticals? .....	28-27
Q 28.23	What if the target company has unregistered trademarks? .....	28-29
<b>Copyrights and Software</b>	.....	28-30
Q 28.24	What are copyrights? .....	28-30
Q 28.25	What rights permit one to update, improve, or modify any software or copyrighted materials? .....	28-30
Q 28.26	How should a company protect its copyrights and software? .....	28-31
Q 28.27	What are the dangers of using open-source software? .....	28-31
Q 28.28	How does one investigate the protection of software and copyright-eligible intellectual property? .....	28-32

<b>Trade Secrets and Know-How</b> .....	28-33
Q 28.29 What are trade secrets? .....	28-33
Q 28.30 How do trade secrets complement patents in protecting a company's technology? .....	28-33
Q 28.31 Can nontechnical matters be protected as trade secrets? .....	28-34
Q 28.32 What due diligence issues arise if the target has licensed trade secrets? .....	28-34
Q 28.33 How should trade secrets and know-how be protected from general distribution? .....	28-34
<b>Other Due Diligence Considerations</b> .....	28-35
Q 28.34 What if someone has a valid security lien against the acquired intellectual property? .....	28-35
Q 28.35 How should a company's employment agreements and employee manuals protect intellectual property rights? .....	28-37
Q 28.36 What due diligence issues may arise with respect to intellectual property litigation? .....	28-37
Q 28.37 What due diligence issues may arise with respect to proceedings before the Patent and Trademark Office? .....	28-38
Q 28.38 What are "march-in" rights? .....	28-39
Q 28.39 Is indemnification typically available for intellectual property infringement? .....	28-39
Q 28.40 How can due diligence review of freedom-to-operate, clearance, and invalidity opinions be addressed without waiving privilege? .....	28-40
Q 28.41 What other IP or IP-related issues should be considered during due diligence? .....	28-40

## Chapter 29 Material Contracts

*Andrew L. Bab & Dmitriy A. Tartakovskiy*

<b>Principal Types of Material Contracts in Health Care Transactions</b> .....	29-2
Q 29.1 What are the principal types of material contracts that a health care target is likely to have? .....	29-2
Q 29.1.1 What are the principal types of material contracts that hospitals and other health care service providers are likely to have? .....	29-3
Q 29.1.2 What are the principal types of material contracts that a pharmaceutical or biotechnology company is likely to have? .....	29-4

*Table of Contents*

---

<b>Change of Control Provisions</b> .....	29-5
Q 29.2 What due diligence should be conducted to determine whether the proposed transaction triggers a change-of-control or anti-assignment provision in any of the target's contracts? .....	29-5
<b>Agreements with Third-Party Payors, Health Care Professionals, and Patient Referral Sources</b> .....	29-6
Q 29.3 What are the key issues in due diligence review of agreements with third-party payors? .....	29-6
Q 29.4 What are the key issues in due diligence review of agreements with health care professionals?.....	29-7
Q 29.5 What are the key issues in due diligence review of agreements with patient referral sources? .....	29-7
<b>Commercial Contracts and Debts</b> .....	29-8
Q 29.6 How should the target's commercial contracts be evaluated with respect to their economic terms? .....	29-8
Q 29.7 What other issues may arise in the target's commercial contracts?.....	29-9
Q 29.8 What issues may arise with respect to the target's outstanding indebtedness?.....	29-10
<b>Agreements Relating to Prior Mergers and Acquisitions</b> .....	29-10
Q 29.9 What issues may arise with respect to the target's acquisition and disposition agreements?.....	29-10
<b>Joint Venture Agreements</b> .....	29-11
Q 29.10 What are the key issues when performing due diligence review on joint venture agreements?.....	29-11
<b>Licenses and Other Contracts Involving Intellectual Property</b> .....	29-13
Q 29.11 What types of agreements relating to intellectual property might a target company have? .....	29-13
Q 29.12 What are the key issues in due diligence review of license-and-collaboration agreements? .....	29-14
Q 29.13 What risks are associated with in-licensing of technology rights? .....	29-15
Q 29.14 What should be the focus when reviewing the target's outbound technology licenses?.....	29-17
Q 29.15 What due diligence concerns arise where the target's research and development agreements address intellectual property ownership and protection? .....	29-17
Q 29.16 What is a material transfer agreement?.....	29-18

## Chapter 30 Environmental Considerations

*Stuart Hammer*

<b>Principal Risks</b> .....	30-2
Q 30.1 Why should parties assess environmental risks in health care transactions? .....	30-2
Q 30.2 What is contamination? .....	30-3
Q 30.3 To what types of environmental claims can a health care company be subject? .....	30-4
Q 30.4 What types of compliance issues arise in health care transactions? .....	30-5
Q 30.5 Should an investor consider risks related to global climate change and greenhouse gas emissions? .....	30-6
<b>Principal Environmental Laws Affecting the Health Care Industry</b> .....	30-7
Q 30.6 What is the Resource Conservation and Recovery Act? .....	30-7
Q 30.7 Which laws regulate medical waste? .....	30-8
Q 30.8 What is the Clean Air Act? .....	30-9
Q 30.9 What is the Toxic Substances Control Act? .....	30-9
Q 30.10 What requirements are imposed on storage tanks? .....	30-9
Q 30.11 What requirements are imposed on dental practices? .....	30-10
Q 30.12 What other environmental statutes may be relevant? .....	30-10
<b>How Purchasers Can Assess Risk</b> .....	30-11
Q 30.13 How can prospective purchasers assess environmental risks? .....	30-11
Q 30.13.1 Which documents should the purchaser review? .....	30-11
Q 30.13.2 Should a purchaser interview the target's personnel? .....	30-12
Q 30.13.3 Should the purchaser commission a Phase I environmental site assessment? .....	30-12
<b>Contract Provisions</b> .....	30-13
Q 30.14 What environmental representations and warranties are typically included in purchase agreements in the health care industry? .....	30-13
Q 30.14.1 What purpose do such representations and warranties serve? .....	30-14
Q 30.15 Are indemnities used? .....	30-14

## Chapter 31 Employee Benefits

*Jonathan F. Lewis & Charles E. Wachsstock*

<b>Diligence Overview</b> .....	31-2
Q 31.1 What are the major elements of diligence relating to executive compensation and employee benefits? .....	31-2
Q 31.2 What benefits information is typically available with respect to a public target?.....	31-3
Q 31.3 Why do single-employer defined benefit pension plans present significant diligence issues? .....	31-5
Q 31.4 Why do retiree medical benefits present significant diligence issues? .....	31-6
<b>Issues Involving Senior Management</b> .....	31-7
Q 31.5 Why do arrangements with senior management present significant diligence issues?.....	31-7
Q 31.6 What are “single-trigger” versus “double-trigger” compensation arrangements? .....	31-8
Q 31.7 What special rules apply to “golden parachutes”?.....	31-9
<b>Issues Involving Unions</b> .....	31-10
Q 31.8 What diligence issues are raised by collective bargaining agreements? .....	31-10
Q 31.9 What are “multiemployer” pension plans? .....	31-11
Q 31.10 For multiemployer plans, what is “withdrawal liability”?.....	31-12
<b>Impact of Health Care Reform</b> .....	31-13
Q 31.11 Is health care reform significant for due diligence regarding employee benefits?.....	31-13
Q 31.12 What is the significance of section 162(m)(6) of the Internal Revenue Code?.....	31-14
<b>Carve-out Issues</b> .....	31-14
Q 31.13 What special considerations apply to carve-out transactions?.....	31-14
Q 31.14 What arrangements may be made for transitional handling of employment benefits?.....	31-15
Q 31.15 What alternatives are available for tax-qualified retirement plans?.....	31-16

## HEALTH CARE MERGERS & ACQUISITIONS AB

---

Q 31.16	What is “controlled group” liability?.....	31-17
Q 31.17	Under what circumstances might the Pension Benefit Guaranty Corporation intervene in an M&A transaction? .....	31-18
<b>Downsizing</b>	.....	31-19
Q 31.18	What is the Worker Adjustment and Retraining Notification Act? .....	31-19
Q 31.19	What antidiscrimination laws may apply in a downsizing? .....	31-20
Q 31.20	Will terminated employees have a right to continued benefits? .....	31-20
<b>Other Notice Requirements</b>	.....	31-20
Q 31.21	What other employment-related SEC filings might be required?.....	31-20
Q 31.22	What other PBGC filings might be required? .....	31-21

## Chapter 32 Foreign Corrupt Practices Act

*Andrew M. Levine & Erich O. Grosz*

<b>Scope of the Statute</b>	.....	32-2
Q 32.1	What is the FCPA?.....	32-2
Q 32.2	Who is subject to the FCPA? .....	32-3
Q 32.3	Who enforces the FCPA? .....	32-3
Q 32.4	What are the potential consequences of violating the FCPA? .....	32-3
Q 32.5	Do other countries have laws similar to the FCPA? .....	32-4
Q 32.6	Why is the health care industry particularly susceptible to FCPA risks? .....	32-5
<b>The Antibribery Provisions</b>	.....	32-6
Q 32.7	What types of payments are prohibited by the FCPA’s antibribery provisions? .....	32-6
Q 32.8	Who qualifies as a “foreign official” under the FCPA?.....	32-6
Q 32.9	What makes a payment “corrupt” for purposes of “obtaining or retaining” business in violation of the FCPA? .....	32-7
Q 32.10	What type of “knowledge” of a subsidiary’s or other affiliate’s conduct is required for liability under the antibribery provisions? .....	32-8
Q 32.11	Can a company be liable for payments made by third parties, such as sales agents, consultants, and distributors? .....	32-8

## Table of Contents

---

Q 32.12	What exceptions are available under the antibribery provisions? .....	32-8
Q 32.13	What affirmative defenses are available under the antibribery provisions? .....	32-9
<b>Exposure of Acquiring Companies</b> .....		32-10
Q 32.14	Is an acquiring company exposed to FCPA liability for the target's violations? .....	32-10
Q 32.15	What is an acquiring company's potential exposure to liability for the target's antibribery violations?.....	32-10
Q 32.16	What is an acquiring company's potential exposure to liability for the target's pre-acquisition violations of the accounting provisions?.....	32-11
<b>Diligence Strategies</b> .....		32-11
Q 32.17	What are some of the benefits of pre-acquisition FCPA diligence?.....	32-11
Q 32.18	What steps should a company take as part of pre-acquisition FCPA diligence? .....	32-13
Q 32.19	What information should be sought during the due diligence process?.....	32-14
Q 32.20	What types of questions should be asked regarding potential FCPA liability?.....	32-14
Q 32.21	Can a company ever conduct too much FCPA diligence prior to an acquisition? .....	32-15
Q 32.22	What if FCPA diligence cannot be completed pre-acquisition? .....	32-16
Q 32.23	What post-acquisition steps are advisable where comprehensive FCPA diligence cannot be completed prior to closing?.....	32-16
Q 32.24	Is requesting a DOJ opinion a viable option? .....	32-18
<b>Compliance Programs</b> .....		32-18
Q 32.25	What factors should be considered in assessing whether a target company has a robust FCPA compliance program? .....	32-18
Q 32.26	What potential FCPA risks should be considered with respect to clinical trials? .....	32-20
Q 32.27	What potential FCPA risks should be considered with respect to sales and marketing programs? .....	32-21
Q 32.28	What potential FCPA risks should be considered with respect to government product approvals, product certifications, and other licensing requirements? .....	32-22

<b>Disclosing Violations to the Government</b> .....	32-22
Q 32.29 In the M&A context, when is it advisable to disclose an FCPA violation to the government?.....	32-22
Q 32.30 What considerations weigh in favor of a voluntary disclosure? .....	32-24
Q 32.31 What considerations militate against a voluntary disclosure? .....	32-25

## **Chapter 33 Real Property**

*Peter J. Irwin*

<b>Separate Ownership of Real Estate</b> .....	33-2
Q 33.1 Are there advantages to having real property held by an entity distinct from the entity conducting health care operations?.....	33-2
<b>Due Diligence Considerations</b> .....	33-3
Q 33.2 What kind of real estate diligence is needed as part of a health care M&A transaction? .....	33-3
Q 33.2.1 What diligence is typically needed for a target's owned properties? .....	33-3
Q 33.2.2 What diligence is typically needed regarding leased properties? .....	33-4
Q 33.2.3 What if the property is the subject of a sale-leaseback arrangement? .....	33-5
Q 33.3 What other issues may arise in real estate diligence?.....	33-6
Q 33.3.1 How does a prospective acquirer review zoning? .....	33-6
Q 33.3.2 When should a prospective acquirer review underlying land use issues? .....	33-6

**PART III**  
**TRANSACTION DOCUMENTATION**

**Chapter 34 Elements of Acquisition Agreements**

*Andrew L. Bab & Dmitriy A. Tartakovskiy*

**Principal Elements** .....34-2

Q 34.1 What are the principal elements of a health care acquisition agreement?.....34-2

**Variations** .....34-3

Q 34.2 What provisions do parties typically focus on in health care M&A transactions? .....34-3

**Chapter 35 Representations and Warranties**

*Andrew L. Bab, Dmitriy A. Tartakovskiy & Jonathan L. Lubin*

**Purposes and Effects**.....35-2

Q 35.1 What is the difference between a representation and a warranty?.....35-2

Q 35.2 How can representations and warranties in acquisition agreements be categorized? .....35-3

Q 35.3 What purposes do representations and warranties serve in health care acquisition agreements?.....35-4

**Typical Provisions in Health Care Deals**.....35-5

Q 35.4 What industry-specific representations and warranties are typically included in health care acquisition agreements?.....35-5

Q 35.5 What industry-specific representations and warranties are typically included in acquisition agreements involving pharmaceutical or biotechnology companies or medical device manufacturers? .....35-6

Q 35.5.1 What representations and warranties relating to legal and regulatory compliance are typical?.....35-6

Q 35.5.2 What representations and warranties relating to intellectual property are typical?.....35-9

Q 35.5.3 What representations and warranties relating to material contracts are typical?.....35-10

Q 35.5.4 What representations and warranties relating to litigation and product liability matters are typical? .....35-11

## HEALTH CARE MERGERS & ACQUISITIONS AB

---

Q 35.6	What additional representations and warranties may be included in purchase agreements relating to product or portfolio acquisitions? .....	35-12
Q 35.7	What industry-specific representations and warranties are typically included in acquisition agreements involving health care providers? .....	35-14
Q 35.7.1	What representations and warranties relating to legal and regulatory compliance are typical? .....	35-14
Q 35.7.2	What representations and warranties relating to the target's participation in Medicare, Medicaid, CHAMPUS, TRICARE, and other federal, state, or local government reimbursement programs are typical? .....	35-17
Q 35.7.3	What representations and warranties relating to the target's accounts receivable and billing practices are typical? .....	35-19
Q 35.7.4	What representations and warranties relating to the target's material contracts are typical? .....	35-19
Q 35.7.5	What representations and warranties relating to the target's licensed personnel and medical staff matters are typical? .....	35-20
Q 35.7.6	What representations and warranties relating to the target's environmental matters are typical? .....	35-21
<b>Limiting the Scope of Representations and Warranties</b> .....		35-23
Q 35.8	How can parties limit the scope of their representations and warranties in health care acquisition agreements? .....	35-23
Q 35.8.1	What is the role of materiality qualifiers? .....	35-23
Q 35.8.2	What is the role of knowledge qualifiers? .....	35-24

## Chapter 36 Covenants and Deal Protection

*Uri Herzberg & Christopher Anthony*

<b>Pre-Closing Covenants</b> .....		36-3
Q 36.1	What types of pre-closing covenants related to the transaction process are typically included in health care M&A agreements? .....	36-3
Q 36.2	What is the interim-conduct-of-business covenant? .....	36-4
Q 36.3	What is "gun jumping"? .....	36-7
Q 36.4	What covenants relating to regulatory approvals and third-party consents may be included in health care acquisition agreements? .....	36-8

## Table of Contents

---

Q 36.5	What is a buyer financing covenant? .....	36-9
Q 36.6	What is a financing cooperation covenant? .....	36-10
Q 36.7	What industry-specific covenants are sometimes included in agreements for the acquisition of pharmaceutical, biotechnology, or medical device companies? .....	36-10
Q 36.8	What industry-specific covenants are sometimes included in agreements for the acquisition of a health care service provider? .....	36-14
Q 36.9	What are the legal consequences of breaching a pre-closing covenant? .....	36-15
<b>Post-Closing Covenants</b> .....		36-15
Q 36.10	What types of post-closing covenants are typically included in health care M&A agreements? .....	36-15
Q 36.11	What is a covenant for further assurances? .....	36-17
Q 36.12	What is a covenant not to compete? .....	36-17
Q 36.13	What are the remedies for a breach of a post-closing covenant? .....	36-20
<b>Deal Protection</b> .....		36-20
Q 36.14	What are deal protection provisions? .....	36-20
Q 36.15	What is a “no-shop” provision? .....	36-21
Q 36.16	What is a termination fee? .....	36-22
Q 36.17	What is a reverse termination fee? .....	36-23

## Chapter 37 Closing Conditions

*Andrew L. Bab, Dmitriy A. Tartakovskiy &  
Chantal Tortoroli*

<b>Mutual and Individual Conditions</b> .....		37-3
Q 37.1	What types of mutual closing conditions typically appear in health care transactions? .....	37-3
Q 37.2	What closing conditions applicable to only one party may appear in health care acquisition agreements? .....	37-3
<b>Conditions Relating to Regulatory Approvals and Third-Party Consents</b> .....		37-5
Q 37.3	What types of regulatory approvals and third-party consents may be included as closing conditions in health care M&A agreements? .....	37-5

## HEALTH CARE MERGERS & ACQUISITIONS AB

---

Q 37.4	What types of antitrust approvals typically constitute closing conditions in health care M&A agreements?.....	37-5
Q 37.5	What other types of regulatory approvals and third-party consents may be included as closing conditions in health care M&A agreements? .....	37-6
Q 37.6	What are typical points of negotiation with respect to closing conditions relating to regulatory approvals and third-party consents?.....	37-7
Q 37.7	How does the structure of the deal affect the choice of regulatory approvals and third-party consents as closing conditions?.....	37-8
<b>The Bringdown Condition and Related Provisions .....</b>		<b>37-9</b>
Q 37.8	What is the bringdown condition?.....	37-9
Q 37.9	Should the bringdown condition require that the representations and warranties be true and correct as of signing as well as of closing? .....	37-10
Q 37.10	Should all of the parties' representations be reaffirmed as of the closing date? .....	37-10
Q 37.11	What materiality standard should be used?.....	37-10
Q 37.12	For what representations is a materiality standard considered inappropriate?.....	37-12
Q 37.13	Is performance of the parties' covenants typically included as a closing condition in health care acquisition agreements?.....	37-12
Q 37.14	What is the purpose of an officer's certificate?.....	37-13
<b>Material Adverse Effect Conditions .....</b>		<b>37-13</b>
Q 37.15	What is a standalone material adverse effect condition? .....	37-13
<b>Conditions Specific to the Business or Industry.....</b>		<b>37-16</b>
Q 37.16	What industry-specific closing conditions may be included in health care acquisition agreements?.....	37-16

## **Chapter 38 Documentation for Indemnification**

*Andrew L. Bab, Dmitriy A. Tartakovskiy &  
Jonathan L. Lubin*

### **Purposes and Types of Indemnification Provisions in Health Care**

#### **Acquisition Agreements .....38-3**

- Q 38.1 What purposes do indemnities serve in health care acquisition agreements?.....38-3
- Q 38.2 What is the interaction of indemnification provisions with purchase price adjustment mechanics?.....38-6
- Q 38.3 What industry-specific special indemnities may be included in health care acquisition agreements?.....38-6
- Q 38.3.1 What industry-specific indemnities may be included in acquisition agreements involving pharmaceutical or biotechnology companies or medical device manufacturers?.....38-8
- Q 38.3.2 What industry-specific indemnities may be included in acquisition agreements involving health care providers? .....38-9

### **Limitations on Indemnification Obligations in Health Care**

#### **Acquisition Agreements .....38-10**

- Q 38.4 How can parties limit the scope of their indemnification obligations in health care acquisition agreements? .....38-10
- Q 38.5 What is a cap?.....38-10
- Q 38.6 What is a basket?.....38-11
- Q 38.7 What is a materiality read-out?.....38-11
- Q 38.8 What is a minimum claim threshold? .....38-12
- Q 38.9 What is a survival period?.....38-13
- Q 38.10 What is the effect of buyer's knowledge of the breach on indemnification? .....38-14
- Q 38.11 What is loss mitigation?.....38-16
- Q 38.12 Is there an obligation to seek available insurance proceeds? .....38-16
- Q 38.13 What is the effect of tax benefits on indemnification obligations? .....38-16

#### **Security for the Indemnifying Party's Obligations.....38-17**

- Q 38.14 What arrangements may be used to secure indemnification obligations in health care transactions? .....38-17
- Q 38.15 What is the difference between an escrow and a holdback?.....38-18

**Transaction Insurance in Health Care Acquisitions**.....38-19  
Q 38.16 What is transaction insurance?.....38-19  
Q 38.17 Do health care transactions present special problems for  
this type of insurance? .....38-19

**Chapter 39 Documentation for License-and-Collaboration Agreements**

*Kevin A. Rinker & Henry Lebowitz*

**Licensing and Collaborative Use**.....39-2  
Q 39.1 Which types of intellectual property may be licensed?.....39-2  
Q 39.2 In what ways may the licensee use the licensed intellectual  
property?.....39-2  
Q 39.3 May the licensee sublicense the intellectual property to  
affiliates or third parties?.....39-3  
Q 39.4 Which party owns intellectual property developed after the  
grant date?.....39-3  
**Defense and Enforcement**.....39-3  
Q 39.5 Which party controls the defense or prosecution of  
infringement claims?.....39-3  
Q 39.6 What are the potential solutions to a third-party  
infringement claim?.....39-4  
Q 39.7 How are recoveries from an enforcement action allocated  
between the licensor and the licensee? .....39-4  
**Representations, Warranties, and Indemnities**.....39-5  
Q 39.8 How do intellectual property representations and warranties  
in a license-and-collaboration agreement compare to those in  
an outright acquisition?.....39-5  
Q 39.9 What are the key indemnities? .....39-5  
**Confidentiality, Duration, and Wind-Down**.....39-6  
Q 39.10 Should confidentiality obligations be included?.....39-6  
Q 39.11 What is the typical duration of a license-and-collaboration  
agreement?.....39-7  
Q 39.12 What are the typical wind-down arrangements after  
termination or expiration of the license-and-collaboration  
agreement? .....39-7

## Chapter 40 Documentation for Joint Ventures

*Sarah A.W. Fitts*

<b>Organization of the Joint Venture</b> .....	40-2
Q 40.1 What legal entities may be used for an equity joint venture? .....	40-2
Q 40.2 What sorts of contributions do the participants make to an equity joint venture? .....	40-5
Q 40.3 What are the key terms of a joint venture agreement? .....	40-6
<b>Objectives</b> .....	40-7
Q 40.4 Should the objectives of the joint venture be addressed in the joint venture agreement? .....	40-7
<b>Management and Governance</b> .....	40-9
Q 40.5 How should management and governance be addressed in the joint venture agreement? .....	40-9
Q 40.6 Should the joint venture have a board of directors? .....	40-9
Q 40.7 What is the role of officers? .....	40-10
Q 40.8 What issues arise with respect to decision making by the joint venture participants? .....	40-10
Q 40.9 What if the decision makers do not agree on a course of action? .....	40-12
<b>Indemnification</b> .....	40-13
Q 40.10 What kinds of losses can be indemnified? .....	40-13
<b>Allocation of Income</b> .....	40-14
Q 40.11 How is income allocated among participants? .....	40-14
<b>Transfer of Interests</b> .....	40-15
Q 40.12 Should there be restrictions on transfers of joint venture interests? .....	40-15
Q 40.12.1 What is a right of first offer? .....	40-16
Q 40.12.2 What is a right of first refusal? .....	40-16
Q 40.12.3 What is a tag-along right? .....	40-17
Q 40.12.4 What are drag-along rights? .....	40-17
Q 40.12.5 What are put and call rights? .....	40-17
Q 40.12.6 What are registration rights? .....	40-18
Q 40.13 What transfer issues arise if a participant's interests are held by a special-purpose company? .....	40-18

<b>Termination</b> .....	40-18
Q 40.14 What are typical circumstances for termination of the joint venture, or the exit of partners?.....	40-18
Q 40.15 What are some important termination issues that should be addressed in the agreement? .....	40-19

**PART IV  
SPECIAL TOPICS**

**Chapter 41 Acquisitions of and Other Investments in U.S. Companies by Non-U.S. Buyers**

*Jeffrey P. Cunard, Ezra Borut, Rick Sofield,  
Robert Dura & Andrew Field*

<b>Statutory Basis</b> .....	41-2
Q 41.1 What is the source of the U.S. government’s authority to review foreign acquisitions of and other investments in U.S. businesses?.....	41-2
<b>Jurisdiction of CFIUS</b> .....	41-3
Q 41.2 What transactions are subject to CFIUS review?.....	41-3
Q 41.2.1 Who is a “foreign person”?.....	41-4
Q 41.2.2 What is a “U.S. business”?.....	41-4
Q 41.3 What types of control transactions are covered?.....	41-5
Q 41.3.1 What constitutes control?.....	41-5
Q 41.3.2 What constitutes national security? .....	41-6
Q 41.3.3 What constitute “critical technologies”?.....	41-8
Q 41.3.4 What factors are considered in assessing whether to file with CFIUS? .....	41-8
Q 41.3.5 What health care–related transactions might raise national security concerns?.....	41-9
Q 41.4 What constitutes a “covered investment”?.....	41-10
Q 41.4.1 What constitutes “material nonpublic technical information”? .....	41-11
Q 41.4.2 What health care transactions might be “covered investments”? .....	41-11
Q 41.5 What real estate transactions are covered?.....	41-11
Q 41.6 What sorts of transactions need to be reviewed by CFIUS? .....	41-12

## Table of Contents

---

<b>Filing a Notice or Declaration</b> .....	41-12
Q 41.7 Is filing with CFIUS required? .....	41-12
Q 41.8 What is the difference between a Notice and a Declaration? .....	41-14
Q 41.9 What are the benefits of filing a Notice or Declaration?.....	41-14
Q 41.10 When should the filing be made? .....	41-14
Q 41.11 What are the contents of the Notice? .....	41-15
Q 41.12 What are the contents of a Declaration? .....	41-16
Q 41.13 Are the Notice, Declaration, and CFIUS review process confidential?.....	41-17
<b>Government Review</b> .....	41-17
Q 41.14 What is the process prior to the filing of a Notice? .....	41-17
Q 41.15 Is there a fee for submitting a filing to CFIUS? .....	41-18
Q 41.16 What happens after filing of the Notice? .....	41-18
Q 41.17 What happens after the filing of a Declaration? .....	41-20
Q 41.18 What happens during the CFIUS review process?.....	41-20
Q 41.19 How should parties decide whether to file a Notice or Declaration? .....	41-22
Q 41.20 What happens at the end of the Notice or Declaration process?.....	41-23
Q 41.21 What are the consequences of breaching a mitigation agreement? .....	41-24
Q 41.22 When may CFIUS initiate review of a transaction?.....	41-25

## **Chapter 42 Health Care M&A Transactions in France**

*Antoine F. Kirry, Antoine d'Ornano & Rosanne Lariven*

<b>Principal Considerations in Structuring Health Care M&amp;A Transactions in France</b> .....	42-5
Q 42.1 What considerations affect the choice between a stock deal and an asset deal?.....	42-5
<b>Stock Deals</b> .....	42-7
Q 42.2 What are the legal requirements for stock deals involving providers of medical services?.....	42-7
Q 42.3 What are the legal requirements for stock deals involving manufacturers of health products?.....	42-8
Q 42.4 What are the legal requirements for stock deals involving biomedical laboratories?.....	42-9

## HEALTH CARE MERGERS & ACQUISITIONS AB

---

<b>Asset Deals</b> .....	42-11
Q 42.5 What are the French law requirements applicable to asset deals generally? .....	42-11
Q 42.6 What are the legal requirements for asset deals involving health care establishments? .....	42-11
Q 42.7 What are the legal requirements for asset deals involving pharmaceutical establishments?.....	42-12
Q 42.8 What are the legal requirements for asset deals involving manufacturers of health products?.....	42-12
Q 42.9 What are the legal requirements for asset deals involving manufacturers of health equipment?.....	42-12
<b>Transfers</b> .....	42-13
Q 42.10 What are the legal requirements for the transfer of intellectual property rights? .....	42-13
Q 42.11 What are the legal requirements for the transfer of marketing authorizations? .....	42-13
<b>Antitrust, Tax, and Social Security Issues</b> .....	42-16
Q 42.12 What antitrust notices are required for health care transactions in France? .....	42-16
Q 42.13 What substantive antitrust rules are applicable? .....	42-17
Q 42.14 What are the tax incentives for the development of pharmaceutical or medical devices under French law?.....	42-19
Q 42.15 What pricing considerations are relevant to health care M&A transactions? .....	42-20
<b>Principal Due Diligence Considerations</b> .....	42-22
Q 42.16 What are the key due diligence considerations in health care M&A transactions in France? .....	42-22
Q 42.17 What are the key due diligence considerations in transactions involving health institutions? .....	42-24
Q 42.18 What are the key due diligence considerations in transactions involving developers or manufacturers of health care products? .....	42-25
Q 42.18.1 What considerations are relevant if the target is a pharmaceutical company? .....	42-25
Q 42.18.2 What considerations are relevant if the target develops medicinal products?.....	42-26
Q 42.18.3 What considerations are relevant if the target develops or manufactures medical devices?.....	42-28

## Table of Contents

---

Q 42.19	What are the operational constraints on health care companies under French law? .....	42-28
Q 42.20	What are the regulatory constraints on manufacturing health care products in France? .....	42-30
Q 42.21	What are the regulatory constraints on the distribution and marketing of health care products in France? .....	42-32
Q 42.21.1	What are the registration and certification requirements? .....	42-32
Q 42.21.2	What testing is required? .....	42-34
Q 42.21.3	What are the distribution constraints? .....	42-35
Q 42.22	What due diligence issues arise with respect to investigations or enforcement actions by governmental agencies involving the target? .....	42-36
Q 42.23	What are the product liability rules applicable to health care products? .....	42-37
Q 42.24	What are the medical malpractice liability rules?.....	42-39
Q 42.25	What are the applicable environment law constraints?.....	42-41
Q 42.26	What are the key intellectual property issues relating to medicinal products and medical devices? .....	42-42
Q 42.27	What are the key personal data issues relating to the health care industry? .....	42-43
Q 42.28	What are the applicable labor law considerations?.....	42-45
Q 42.29	Are there any issues related to foreign anticorruption programs?.....	42-48
<b>Transaction Documents</b> .....		42-49
Q 42.30	What special issues should be addressed in drafting and negotiating transaction documents in health care M&A transactions in France? .....	42-49
Q 42.31	Is the opinion of the <i>Comité Social et Economique</i> required? .....	42-51
Q 42.32	How should the transfer of permits be addressed?.....	42-51
Q 42.33	Are any foreign investment approvals required? .....	42-52
Q 42.34	What are the special documentation requirements in stock deals? .....	42-52
Q 42.35	What are the special documentation requirements in asset deals? .....	42-53
Q 42.36	What are some typical issues to be addressed in a licensing or collaborative arrangement?.....	42-54

**Chapter 43 Health Care M&A Transactions in Germany**

*Peter Wand*

<b>Regulation of Hospitals</b> .....	43-13
Q 43.1 How is a hospital operated under German law? .....	43-13
Q 43.2 What are the requirements for patient data protection in German hospitals?.....	43-14
Q 43.3 How are German hospitals financed? .....	43-22
<b>Regulation of Medical Care Centers</b> .....	43-27
Q 43.4 What is a medical care center and how is it connected to the health care sector? .....	43-27
Q 43.5 How are providers of contractual medical care regulated, and to which extent does that regulation apply to medical care centers? .....	43-28
Q 43.6 What are further key aspects regarding the regulation of medical care centers? .....	43-31
Q 43.7 Why are medical care centers of interest to hospitals and external investors?.....	43-32
<b>Regulation of Medicinal Products</b> .....	43-34
Q 43.8 What regulatory regime governs the development, manufacture, and distribution of medicinal products? .....	43-34
Q 43.9 What is a medicinal product? .....	43-35
Q 43.10 What are the requirements for developing medicinal products in Germany? .....	43-35
Q 43.11 What are the rules facilitating the development of generic medical products? .....	43-40
Q 43.12 What are the regulatory requirements for manufacturing medicinal products in Germany? .....	43-41
Q 43.13 What are the regulatory requirements for marketing medicinal products in Germany? .....	43-42
Q 43.14 What are the national authorization procedures in Germany?.....	43-43
Q 43.15 What are the European authorization procedures?.....	43-46
Q 43.15.1 What is the centralized procedure in the EU? .....	43-46
Q 43.15.2 What are the Decentralized Procedure and the Mutual Recognition Procedure in the EU? .....	43-47
Q 43.16 What are the pricing concerns in connection with the distribution of medicinal products in Germany? .....	43-48

## Table of Contents

---

Q 43.17	What are the basic price regulations for medicinal products in Germany? .....	43-50
Q 43.18	How are insured persons reimbursed for medicinal product costs? .....	43-52
Q 43.19	What are further obligations when distributing medicinal products in Germany? .....	43-53
<b>Regulation of Medical Devices</b> .....		43-54
Q 43.20	What is the regulatory regime that governs the development, manufacture, and distribution of medical devices in Germany? .....	43-54
Q 43.21	What are the requirements for developing and manufacturing medical devices in Germany? .....	43-56
Q 43.22	What are the requirements for distributing medical devices in Germany? .....	43-58
Q 43.23	What are the key provisions of the latest EU Regulation on medical devices? .....	43-59
Q 43.24	What are the pricing concerns in connection with the distribution of medical devices in Germany? .....	43-61
Q 43.25	What is pharmacovigilance? .....	43-61
<b>Product Liability and Medical Malpractice</b> .....		43-63
Q 43.26	What special product liability rules apply to medicinal products and medical devices? .....	43-63
<b>Regulation of Health Care Advertising</b> .....		43-66
Q 43.27	What rules govern advertising in the health care sector? .....	43-66
<b>Health Care M&amp;A Issues</b> .....		43-69
Q 43.28	What are the key considerations in structuring a health care M&A transaction in Germany? .....	43-69
<b>Stock Transactions</b> .....		43-70
Q 43.29	What are the key legal considerations in connection with stock transactions? .....	43-70
Q 43.29.1	What are the considerations for partnerships? .....	43-71
Q 43.29.2	What are the considerations for limited liability companies? .....	43-71
Q 43.29.3	What are the considerations for stock corporations and partnerships limited by shares? .....	43-72
Q 43.30	What are the rights of the target's employees and their representatives in stock transactions? .....	43-73

## HEALTH CARE MERGERS & ACQUISITIONS AB

---

Q 43.31	What are the tax considerations in stock transactions? .....	43-74
Q 43.32	What are the health care specific issues in stock transactions?.....	43-75
<b>Asset Transactions</b> .....		<b>43-77</b>
Q 43.33	What are the key legal considerations in connection with asset transactions?.....	43-77
Q 43.34	What are the rules governing the transfer of assets, liabilities, and contracts? .....	43-77
Q 43.35	What are the rights of the target company’s employees and their representatives in asset transactions?.....	43-79
Q 43.36	What are the tax considerations in asset transactions? .....	43-83
Q 43.37	What are the health care–specific issues in asset transactions?.....	43-84
Q 43.38	What are the key legal considerations in connection with a transfer of intellectual property rights?.....	43-87
<b>Merger Control, Data Protection, and Other Restrictions</b> .....		<b>43-89</b>
Q 43.39	What are the key merger control considerations in connection with health care M&A transactions in Germany?.....	43-89
Q 43.40	What are the key data protection considerations in German M&A transactions? .....	43-92
Q 43.41	Are there any restrictions on foreign investment? .....	43-94
Q 43.42	Are there applicable foreign exchange controls or reporting requirements?.....	43-99
<b>Due Diligence</b> .....		<b>43-99</b>
Q 43.43	What are the key due diligence considerations in health care M&A transactions in Germany? .....	43-99
Q 43.44	What are the key due diligence considerations in connection with the sale of a hospital business?.....	43-100
Q 43.44.1	What is the importance of determining the legal status of the target hospital? .....	43-101
Q 43.44.2	What issues arise regarding the financing arrangements of the target hospital?.....	43-101
Q 43.44.3	What are the potential issues relating to sensitive health data?.....	43-101
Q 43.45	What are the key due diligence considerations in connection with the sale of a pharmaceutical or medical devices business? .....	43-102
Q 43.45.1	Why is it important to determine the legal status of the target’s products?.....	43-104

## Table of Contents

---

Q 43.45.2	Why is it important to determine whether the target is in possession of necessary marketing authorizations?.....	43-105
Q 43.45.3	What are the potential issues relating to the prescription status and off-label use of the target company's medicinal products?.....	43-106
Q 43.45.4	What are the potential issues relating to pricing and eligibility for health insurance reimbursement?.....	43-107
Q 43.45.5	What are the potential pharmacovigilance and product liability issues? .....	43-108
Q 43.45.6	What are the potential issues relating to the protection of intellectual property rights? .....	43-109

### **Chapter 44 Health Care M&A Transactions in Russia**

*Anna V. Maximenko & Elena M. Klyuchareva*

<b>The Health Care Industry in Russia</b> .....	44-2	
Q 44.1	What are Russia's development goals for the health care industry? .....	44-2
Q 44.2	What legislation affects the health care market? .....	44-3
Q 44.3	What roles does the Russian government play in the health care industry? .....	44-5
<b>Structuring Health Care M&amp;A Transactions in Russia</b> .....	44-6	
Q 44.4	How are health care M&A transactions usually structured in Russia? .....	44-6
Q 44.4.1	Why are stock deals more common than asset deals?.....	44-7
Q 44.4.2	What are typical offshore transactions? .....	44-7
Q 44.5	What types of companies do health care M&A transactions in Russia primarily involve?.....	44-8
Q 44.6	What types of corporate reorganizations are used in M&A activity in the health care sector?.....	44-9
Q 44.7	Are there restrictions on foreign ownership of Russian companies operating in the health care market?.....	44-10
Q 44.8	What regulatory approvals are required for M&A transactions in the Russian health care market? .....	44-12
Q 44.8.1	What transactions require competition clearance? .....	44-12
Q 44.8.2	What transactions require strategic investment clearance? .....	44-14
Q 44.8.3	What transactions require countersanctions clearance? .....	44-15

## HEALTH CARE MERGERS & ACQUISITIONS AB

---

<b>Key Due Diligence Considerations</b> .....	44-16
Q 44.9 What challenges do buyers face in acquisitions of Russian health care companies?.....	44-16
Q 44.10 What are the key issues in conducting due diligence of a Russian health care company?.....	44-18
Q 44.11 What are the potential issues relating to the seller's title to the shares or assets of the target company?.....	44-19
Q 44.11.1 What is a void transaction?.....	44-19
Q 44.11.2 What is a voidable transaction?.....	44-20
Q 44.12 What types of health care activities are subject to licensing?.....	44-20
Q 44.13 What are the principal industry-specific regulatory requirements?.....	44-21
Q 44.13.1 What is state registration of pharmaceuticals and medical equipment?.....	44-22
Q 44.13.2 What is state regulation of pricing?.....	44-23
Q 44.13.3 What are the key regulatory requirements for the manufacture of pharmaceuticals?.....	44-24
Q 44.13.4 What are the requirements for the storage of pharmaceuticals?.....	44-25
Q 44.13.5 What are the applicable disclosure rules with respect to side effects?.....	44-25
Q 44.13.6 What are the standards and procedures for the provision of medical services?.....	44-25
Q 44.13.7 What are the rules for accreditation of employees engaged in performing medical or pharmaceutical activities?.....	44-26
Q 44.13.8 What are the applicable sanitary rules?.....	44-26
Q 44.13.9 What are the applicable restrictions on advertising?.....	44-26
Q 44.13.10 What preferences exist for pharmaceuticals originating from the Eurasian Economic Union?.....	44-27
Q 44.14 How can intellectual property rights to pharmaceuticals and medical equipment be established and protected under Russian law?.....	44-28
Q 44.15 Are Russian anticorruption requirements consistent with international standards?.....	44-29
Q 44.16 What are the main labor safety and environmental requirements affecting the Russian health care industry?.....	44-29
Q 44.17 Can information relating to litigation matters and other disputes involving the target company be obtained from public sources?.....	44-30

## Table of Contents

---

<b>Choice of Law</b> .....	44-31
Q 44.18 Can the parties choose non-Russian law to govern the deal? .....	44-31
<b>Arbitration</b> .....	44-32
Q 44.19 What dispute resolution mechanisms are typically used in health care M&A transactions in Russia?.....	44-32
<b>Chapter 45 Health Care M&amp;A Transactions in the United Kingdom</b>	
<i>Alison Dennis, Suzy Davis, Victoria Hordern, Katie Chandler, Helen Farr, Graham Samuel-Gibbon, Elizabetta Rotondo &amp; Nicholas Vollers</i>	
<b>Initial Transaction Considerations</b> .....	45-6
Q 45.1 What considerations affect the choice between a share deal and an asset deal? .....	45-6
Q 45.2 What are the English law requirements applicable to share deals generally? .....	45-8
Q 45.3 What are the English law requirements applicable to asset deals generally? .....	45-10
Q 45.4 What are the key due diligence considerations in health care M&A transactions in the United Kingdom? .....	45-11
<b>Potential for Government Intervention in Health Care Mergers and Acquisitions in the UK</b> .....	45-14
Q 45.5 What antitrust notifications are required for health care transactions in the United Kingdom? .....	45-14
Q 45.6 What substantive antitrust rules are applicable? .....	45-15
Q 45.7 What other governmental interventions are possible? .....	45-18
<b>Regulatory Requirements in Health Care Mergers and Acquisitions</b> .....	45-21
Q 45.8 What are the regulatory requirements for providers of medical services and how are these relevant to dealings in their stock or assets? .....	45-21
Q 45.9 What are the regulatory requirements for manufacturers of medicinal products?.....	45-23
Q 45.9.1 How are these regulations relevant to dealings in stock or assets of their company? .....	45-23

## HEALTH CARE MERGERS & ACQUISITIONS AB

---

Q 45.10	What are the regulatory requirements for manufacturers of medical devices? .....	45-24
Q 45.10.1	How are these regulatory requirements relevant to dealings in stock or assets of their company? .....	45-26
Q 45.11	What are the regulatory requirements for human tissue? .....	45-26
Q 45.12	What anticorruption laws apply? .....	45-27
<b>Transfers of Intellectual Property Rights</b> .....		45-28
Q 45.13	What are the legal requirements for the transfer of intellectual property rights? .....	45-28
<b>Tax, Labor, and Privacy Issues in Mergers and Acquisitions</b> .....		45-29
Q 45.14	What are the tax incentives for the development of pharmaceutical or medical devices under UK law? .....	45-29
Q 45.15	What are the applicable labor law considerations? .....	45-30
Q 45.16	What are the key personal data issues relating to the health care industry? .....	45-34
<b>Product Liability, Medical Malpractice, and Environmental Issues in Mergers and Acquisitions</b> .....		45-36
Q 45.17	What are the product liability rules applicable to health care products? .....	45-36
Q 45.18	What are the medical malpractice liability rules? .....	45-39
Q 45.19	What are the applicable environmental law constraints? .....	45-41
<b>Transaction Documents</b> .....		45-42
Q 45.20	What special issues should be addressed in drafting and negotiating transaction documents in health care M&A transactions in England? .....	45-42
Q 45.21	How should the transfer of permits be addressed? .....	45-43
Q 45.22	What are the special documentation requirements in share deals? .....	45-44
Q 45.23	What are the special documentation requirements in asset deals? .....	45-44

## Chapter 46 Health Care M&A Transactions in Canada

*Cheryl Satin & Megan Shaw*

<b>Regulatory Environment</b> .....	46-3
Q 46.1 What is Health Canada? .....	46-3
Q 46.2 What role do the provinces play? .....	46-4
Q 46.3 What is the role of the Patented Medicine Prices Review Board? .....	46-5
Q 46.4 How is the advertising of health care products regulated? .....	46-5
Q 46.5 Is there self-regulation in the industry? .....	46-6
Q 46.6 What legislation governs pharmaceutical products, medical devices, and natural health products in Canada? .....	46-7
Q 46.6.1 What is the scope of the Food and Drugs Act? .....	46-7
Q 46.6.2 What criminal laws are applicable? .....	46-7
Q 46.6.3 Are there applicable provincial laws as well? .....	46-8
Q 46.6.4 What is the effect of the Patent Act? .....	46-8
Q 46.6.5 What competition laws apply? .....	46-8
<b>Structuring the Transaction and Obtaining Regulatory Approvals</b> .....	46-9
Q 46.7 What considerations affect the choice of a share purchase versus an asset purchase? .....	46-9
Q 46.8 What is the general process for transferring licenses and approvals for pharmaceutical and medical device products? .....	46-10
Q 46.9 What notices and approvals do health regulatory authorities require in connection with transactions involving pharmaceutical products? .....	46-10
Q 46.10 What notices and approvals do health regulatory authorities require in connection with transactions involving medical device products? .....	46-12
<b>Competition Law</b> .....	46-14
Q 46.11 What mergers are subject to Canadian competition laws? .....	46-14
Q 46.12 What are the thresholds that trigger a duty to give notice of a merger? .....	46-14
Q 46.12.1 What is the effect of the Canadian thresholds as compared to the lower U.S. thresholds? .....	46-15
Q 46.13 What substantive test is applied to mergers under Canadian competition/antitrust laws? .....	46-17
Q 46.14 What is the current enforcement policy regarding the health care industry? .....	46-17

## HEALTH CARE MERGERS & ACQUISITIONS AB

---

Q 46.15	In what ways does the Canadian Competition Bureau cooperate with agencies in other countries? .....	46-18
Q 46.16	What are some examples of transactions that have raised competition concerns? .....	46-19
<b>Investment Canada Act</b> .....		46-22
Q 46.17	Are there any restrictions on foreign investment in the health care industry in Canada? .....	46-22
<b>Bulk Sales</b> .....		46-23
Q 46.18	Is compliance with bulk sales legislation required? .....	46-23
<b>Some Due Diligence Considerations</b> .....		46-23
Q 46.19	What are the legal requirements for transferring material contracts? .....	46-23
Q 46.19.1	Should notice be given to the counterparty in any case? .....	46-24
Q 46.20	What issues should be considered relating to third-party distribution arrangements? .....	46-24
Q 46.21	What are the anticorruption risk considerations? .....	46-26
<b>Privilege</b> .....		46-27
Q 46.22	What privileges are recognized in Canadian law? .....	46-27
Q 46.22.1	What is solicitor-client privilege? .....	46-27
Q 46.22.2	What is litigation privilege? .....	46-27
Q 46.22.3	What is settlement privilege? .....	46-28
Q 46.22.4	What is common interest privilege? .....	46-28
Q 46.23	When documents need to be disclosed, what should be done to preserve a potential claim for common interest privilege? .....	46-28
<b>Anti-Spam Laws</b> .....		46-29
Q 46.24	What restrictions apply to sending commercial electronic messages? .....	46-29
Q 46.25	What are the penalties for violations? .....	46-30
Q 46.26	What due diligence is appropriate? .....	46-30
<b>Transaction Documents</b> .....		46-31
Q 46.27	What documentation is typically required in a share purchase? .....	46-31

## Table of Contents

---

Q 46.28	What documentation is typically required in an asset purchase? .....	46-31
Q 46.28.1	What is the value of a separate transfer agreement relating to Canadian assets? .....	46-32
Q 46.29	What is a transition services agreement? .....	46-32
<b>Product Liability</b> .....		46-33
Q 46.30	Are class actions used in product liability cases? .....	46-33
Q 46.31	Are individual actions used in product liability cases?.....	46-34
Q 46.32	What is the basis for a product liability claim? .....	46-34
Q 46.33	Who is potentially liable? .....	46-35
Q 46.34	What damages may be available? .....	46-35
Q 46.35	Where can one find public information about claims against the target? .....	46-36
<b>Anticorruption Laws</b> .....		46-36
Q 46.36	What are the main Canadian anticorruption statutes? .....	46-36
Q 46.37	How does the CFPOA address corruption?.....	46-36
Q 46.37.1	Could “foreign public officials” include non-Canadian health care professionals? .....	46-37
Q 46.37.2	What payments are permitted as exceptions? .....	46-38
Q 46.37.3	What are the penalties for violations?.....	46-38
Q 46.38	How does the Criminal Code address corruption?.....	46-39
Q 46.38.1	When is a health care professional a “government official”? .....	46-39
Q 46.38.2	Do the Criminal Code provisions reach private sector activity? .....	46-40
Q 46.38.3	What are the penalties for violation of the anticorruption offenses? .....	46-40
Q 46.39	How does Canadian anticorruption law compare to that of the United States?.....	46-41
Q 46.40	How does Canadian anticorruption law compare to that of the United Kingdom? .....	46-41
Q 46.41	Can an acquiring company be liable for the target’s anticorruption violations?.....	46-42
<b>Procurement System</b> .....		46-43
Q 46.42	What is the legal framework applicable to the procurement of health care goods and services in Canada? .....	46-43

## HEALTH CARE MERGERS & ACQUISITIONS AB

---

- Q 46.43 What information does a purchaser need to know about a target's eligibility to participate in the Canadian public procurement process? .....46-45
- Q 46.44 If a target has a bid pending in a binding competitive government procurement, is there anything a purchaser should consider? .....46-48

### **Chapter 47 Health Care M&A Transactions in Japan**

*Taisuke Igaki, Yoko Kasai & Satoshi Yumura*

#### **Overview of the Health Care Industry in Japan.....47-2**

- Q 47.1 What is the structure of the health care insurance system in Japan?.....47-2
- Q 47.2 How are the market prices of drugs determined?.....47-3
- Q 47.3 How are the market prices of medical devices determined?.....47-4

#### **Structuring Health Care M&A Transactions in Japan.....47-4**

- Q 47.4 How are transactions typically structured?.....47-4
- Q 47.5 What are the primary differences among the structures?.....47-5
- Q 47.6 What are the differences from a tax perspective?.....47-6
- Q 47.6.1 What is the tax treatment of a stock transfer? .....47-6
- Q 47.6.2 What is the tax treatment of a business transfer? .....47-7
- Q 47.6.3 What is the tax treatment of a company split?.....47-7
- Q 47.7 Are there cases where a buyer takes over the tax liabilities of the target? .....47-8

#### **Corporate Procedures Required for Each Structure.....47-9**

- Q 47.8 What are the required procedures for stock transfers? .....47-9
- Q 47.9 What are the required procedures for business transfers? .....47-11
- Q 47.10 What are the required procedures for company splits? .....47-12
- Q 47.10.1 What procedures are required under the Companies Act? .....47-14
- Q 47.10.2 What is a simplified company split? .....47-14
- Q 47.10.3 How are employee relationships handled in a company split?.....47-15

*Table of Contents*

---

<b>Regulatory Framework and Compliance in the Health Care Industry</b> .....	47-16
<i>Pharmaceuticals and Medical Devices</i> .....	47-16
Q 47.11 What is the primary law governing the health care industry in Japan? .....	47-16
Q 47.12 What is a “drug” under the Pharmaceuticals and Medical Devices Act? .....	47-16
Q 47.13 What is a “medical device” under the Pharmaceuticals and Medical Devices Act?.....	47-17
<i>Regulatory Pathways; Licenses and Approvals</i> .....	47-18
Q 47.14 What are the regulatory pathways for the development of drugs and medical devices?.....	47-18
Q 47.15 What are the marketing authorizations for drugs? .....	47-18
Q 47.15.1 What is a marketing authorization holder? .....	47-19
Q 47.15.2 What is the role of the drug master file system?.....	47-19
Q 47.16 What business licenses are required for manufacturing drugs? .....	47-19
Q 47.17 What business licenses are required for marketing drugs?.....	47-20
Q 47.18 What are the required regulatory approvals for the marketing of medical devices and in vitro diagnostic drugs? .....	47-20
Q 47.19 What business licenses are required for manufacturing medical devices and in vitro diagnostic drugs? .....	47-21
Q 47.20 What business licenses are required for marketing medical devices and in vitro diagnostic drugs? .....	47-21
Q 47.21 What are the regulatory approvals and business licenses for marketing, manufacturing, and distributing regenerative medicine products?.....	47-22
Q 47.21.1 What marketing authorization is needed for regenerative medicine products?.....	47-22
Q 47.21.2 What marketing business license is needed for regenerative medicine products?.....	47-22
Q 47.21.3 What manufacturing business license is needed for regenerative medicine products?.....	47-23
Q 47.22 What are the procedures for transferring marketing authorizations for drugs and medical devices in connection with health care M&A? .....	47-23
Q 47.22.1 What are the procedures where a stock transfer is involved? .....	47-23
Q 47.22.2 What are the procedures where the transaction is a merger, company split, or business transfer? .....	47-23

## HEALTH CARE MERGERS & ACQUISITIONS AB

---

Q 47.23	What regulations govern preclinical studies and clinical trials? .....	47-25
Q 47.24	What post-market safety monitoring is in place for medicinal products?.....	47-26
Q 47.25	What is the relief system for adverse drug reactions in Japan? .....	47-26
Q 47.26	What are the restrictions on advertising medicinal products?.....	47-27
Q 47.27	What are the restrictions on improper promotional activities for drugs or medical devices?.....	47-27
Q 47.27.1	What is the Fair Competition Code? .....	47-27
Q 47.27.2	Is resale price maintenance prohibited? .....	47-28
Q 47.28	What are the major regulatory compliance issues in the health care industry in Japan?.....	47-28
<b>Other Key Due Diligence Considerations</b> .....		47-29
Q 47.29	How can intellectual property rights in drugs be protected under Japanese patent law?.....	47-29
Q 47.29.1	What is the term of patent protection? .....	47-29
Q 47.29.2	Can generic versions of drugs be approved during the patent term? .....	47-30
Q 47.30	Is there any “data exclusivity” or “market exclusivity” for drugs in Japan? .....	47-30
Q 47.31	What are the key issues in contract review for health care M&A due diligence?.....	47-31
Q 47.32	What are the merger control regulations in Japan? .....	47-31
Q 47.33	Are there any restrictions on foreign investment? .....	47-32

## Chapter 48 Health Care M&A Transactions in India

*Anand Mehta, Agranee Kapoor & Stephanie Nazareth*

<b>Background to Health Care in India</b> .....		48-3
Q 48.1	How is health care regulated in India?.....	48-3
Q 48.2	What is the role of private players in the health care sector?.....	48-5
Q 48.3	What is the approximate market size of the health care sector in India? .....	48-5
<b>Structuring an M&amp;A Transaction in India’s Health Care Sector</b> .....		48-6
Q 48.4	What are the different ways in which a health care deal can be structured in India?.....	48-6

## Table of Contents

---

Q 48.5	What is the legal regime governing an M&A deal in India? .....	48-7
Q 48.6	How are listed companies affected differently in M&A transactions compared to private companies? .....	48-7
Q 48.7	How does a minority squeeze-out work under Indian laws? .....	48-8
Q 48.8	How are transactions involving nonresident parties structured and what is the framework governing such transactions? .....	48-9
Q 48.9	What foreign exchange laws govern a health care M&A deal? .....	48-10
<b>Relevant Legal Regimes</b> .....		48-12
Q 48.10	What are the competition law concerns in India? .....	48-12
Q 48.11	What are the tax implications of a health care M&A transaction? .....	48-14
Q 48.12	What is the framework of labor laws in India? .....	48-15
Q 48.13	What are the anti-corruption laws in place in India? .....	48-16
Q 48.14	What are the main concerns about intellectual property in relation to e-health? .....	48-18
Q 48.14.1	How should patents be handled? .....	48-18
Q 48.14.2	How should nonpatentable technology and know-how be handled? .....	48-18
Q 48.14.3	How should copyrights be handled? .....	48-19
Q 48.14.4	How should designs be handled? .....	48-20
Q 48.14.5	How should trademarks be handled? .....	48-20
<b>Due Diligence Aspects of a Deal</b> .....		48-21
Q 48.15	What are the due diligence aspects of a health care M&A deal? .....	48-21
Q 48.16	What are the key considerations that would make a target entity more viable? .....	48-22
<b>Recent Developments and Trends in the Indian Health Care Sector</b> .....		48-23
Q 48.17	How does India deal with new and rare diseases? .....	48-23
Q 48.18	How is artificial intelligence contributing to the health care sector? .....	48-24
Q 48.19	How is teleconsultation improving access to health care? .....	48-25
Q 48.20	How is last-mile delivery improving access to health care? .....	48-27
Q 48.21	How are medical devices regulated? .....	48-28
Q 48.22	What lies ahead for the health care sector? .....	48-30
<b>Index</b> .....		I-1

